**Title page - consensus document**

**Exercise therapy for chronic symptomatic peripheral artery disease: a clinical consensus document of the ESC Working Group on Aorta & Peripheral Vascular Diseases in collaboration with the European Society of Vascular Medicine, and the European Society for Vascular Surgery**

**Lucia Mazzolai1\*#, Jill Belch2#, Maarit Venermo3#**, Victor Aboyans4, Marianne Brodmann5, Alessandra Bura-Rivière6, Sebastien Debus7, Christine Espinola-Klein8, Amy E. Harwood9, John A. Hawley10, Stefano Lanzi1, Juraj Madarič11, Guillaume Mahé12,13, Davide Malatesta14, Oliver Schlager15, Arno Schmidt-Trucksäss16, Chris Seenan17, Henrik Sillesen18, Garry A. Tew19, Adriana Visonà20

**# shared first authors**

1 Angiology Department, Lausanne University Hospital, University of Lausanne, Switzerland

2 Institute of Cardiovascular Research, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom

3 Department of Vascular Surgery, Abdominal Center, Helsinki University Hospital, Haartmaninkatu 4, 00029 Helsinki; University of Helsinki, Yliopistonkatu 4, 00100 Helsinki

4 Department of Cardiology, Dupuytren-2 University Hospital, and EpiMaCT, INSERM 1094/IRD270, Limoges University, Limoges, France

5 Division of Angiology, Department of Internal Medicine, Medical University, Graz, Austria

6 Department of Vascular Medicine, Toulouse University Hospital, France

7 Department of Vascular Medicine, Vascular Surgery - Angiology - Endovascular Therapy University of Hamburg-Eppendorf Hamburg Germany

8 Center of Cardiology, Department of Cardiology III-Angiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany

9 Department for Sport and Exercise Sciences, Manchester Metropolitan University, Manchester, UK

10 Exercise and Nutrition Research Programme, Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, VIC, Australia

11 Department of Angiology, Comenius University and National Institute of Cardiovascular Diseases, Bratislava, Slovakia

12 Vascular Medicine Unit, Centre Hospitalier Universitaire de Rennes, 35033 Rennes, France

13 INSERM CIC 1414, Université de Rennes, 35033 Rennes, France

14 Institute of Sport Sciences, University of Lausanne, Lausanne, Vaud, Switzerland

15 Division of Angiology, Department of Medicine II, Medical University of Vienna, Vienna, Austria

16 Division of Sport and Exercise Medicine, Department of Sport, Exercise and Health, University of Basel, Basel, Switzerland

17 School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK

18 Department of Vascular Surgery, Rigshospitalet, Blegdamsvej 9, Copenhagen, DK, 2100, Denmark, and Department of Clinical medicine, University of Copenhagen

19 Institute for Health and Care Improvement, York St John University, York, YO31 7EX, UK

20 Angiology Unit, Ospedale Castelfranco Veneto, Castelfranco Veneto, Italy

**\*Corresponding author**

Prof. Lucia Mazzolai

Division of Angiology, Heart and Vessel Department

Lausanne University Hospital

Switzerland - Ch. de Mont-Paisible 18

1011 Lausanne, Switzerland

Tél. +41 021 314 07 68

[lucia.mazzolai@chuv.ch](mailto:lucia.mazzolai@chuv.ch)

**Abstract**

All guidelines worldwide strongly recommend exercise as a pillar of the management of patients affected by lower extremity peripheral artery disease (PAD). Exercise therapy in this setting presents different modalities, and a structured programme provides optimal results. This clinical consensus paper is intended for clinicians to promote and assist for the set-up of comprehensive exercise programmes to best advice in patients with symptomatic chronic PAD. Different exercise training protocols specific for patients with PAD are presented. Data on patient assessment and outcome measures are narratively described based on the current best evidence. The document ends by highlighting disparities in access to supervised exercise programmes across Europe, and the series of gaps for evidence requiring further research.

**Graphical abstract**



**Introduction**

Physical activity, including regular exercise, is one of the pillars of cardiovascular (CV) health and a major component of management of patients with most CV diseases (CVD). In 2020, the European Society of Cardiology (ESC) issued a guideline document addressing the main aspects of exercise therapy and sports practice for cardiac diseases 1.

In this consensus document, the acronym PAD will be used to indicate lower extremity peripheral artery disease. PAD is one of the most prevalent clinical presentations of atherosclerotic disease, affecting approximately 237 million people worldwide 2. The first symptoms of PAD are usually related to walking impairment, and the 2017 ESC/European Society for Vascular Surgery (ESVS) guidelines on the management of PAD underscore the importance of exercise therapy, preferably supervised, for the management of patients with intermittent claudication (IC) 3. Similarly, the 2019 PAD guidelines of the European Society of Vascular Medicine (ESVM) encourage structured exercise for symptomatic PAD patients 4.However, none of the aforementioned documents provided in-depth guidance for exercise therapy in this specific setting.

To address this gap, the ESC Working Group on Aorta & Peripheral Vascular Disease, the ESVM, and the ESVS joined in a collaborative effort aiming to provide a roadmap and guidance for the set-up and implementation of exercise therapy programmes for patients with PAD.

**Consensus statements**

* **1. In patients with PAD and exercise-induced limb symptoms due to vascular origin, supervised exercise programmes should be the first line treatment modalities.**
* **2. In patients with PAD undergoing revascularisation, supervised exercise programmes should be included as adjuvant therapy.**
* **3. Supervised exercise programmes should ideally be coordinated by vascular physicians, and sessions should be ideally supervised by clinical exercise physiologists or physiotherapists.**
* **4. Prior to exercise training initiation, complete medical history and examination, and screening for contraindications should be investigated.**
* **5. Measures of walking ability, functional status, and quality of life should be assessed at the beginning and end of the programme to determine the patient’s response to exercise training. Clinical outcomes and patient experience should also be documented.**
* **6. Walking training (overground, pole striding, treadmill) should be proposed as first line exercise modality. When walking is not an option, alternative training modalities (resistance and strength training, arm-cranking, cycling, combinations of exercise) should be performed.**
* **7. The training frequency should be at least three times per week.**
* **8. The training session duration should last a minimum of 30 min.**
* **9. The training programme duration should last a minimum of 3 months.**
* **10. Both claudication pain (A) and exercise intensity (B, based on common training intensity measures such as heart rate or the rate of perceived exertion (RPE) on Borg’s scale) should be evaluated during training sessions:**

1. **The current consensus is that patients should exercise to moderate-high claudication pain based on strong evidence. However, some trials have recently demonstrated improvement in walking ability using a low, or no pain approach. As claudication pain is a commonly cited barrier to exercise, universally prescribing high-pain exercise may lead to poor uptake of, and adherence to, exercise training programmes. A more flexible approach to exercise prescription may therefore be required, considering the patient’s needs and preferences, and what might achieve a high level of (long term) adherence.**
2. **Following a “lead-in period” of low-to-moderate exercise intensity, a gradual progression to vigorous/high exercise intensity may be proposed if well tolerated by the patient.**

* **11. If supervised exercise is not available or feasible, a structured community- or home-based exercise programme that includes behaviour change techniques should be proposed.**
* **12. Supervised exercise programmes should include structured education and counselling on cardiovascular disease and PAD risk factor reduction. Smoking cessation should be a cornerstone of risk factor counselling.**
* **13. Following initial exercise training (supervised or home-based), patients are encouraged to sustain lifelong and high levels of regular physical activity.**

**Pathophysiology of intermittent claudication and functional impairment**

IC is characterised by exertional leg pain limiting walking ability 5-7. PAD induces a wide range of exercise-related symptoms experienced by nearly half of the PAD population 8. The classical IC symptomology was first defined as calf pain, discomfort or fatigue appearing during exercise and forcing the patient to stop 9. Typically, IC is relieved within 2-5 min after discontinuation of exertion 9. Apart from this typical symptom, it is now admitted that some patients with PAD may present atypical exercise-induced limb symptoms 10. These may be localised in lower limb muscles other than calves, may be present at rest, may be described by patients as “burning”, “compressive” feeling, or just “fatigue” without pain and may mimic limb pain due to spinal stenosis. Exercise-induced limb symptoms in PAD are caused by a metabolic mismatch between oxygen demand and supply 5. The mismatch is linked to the reduction of the arterial lumen by the atherosclerosis process, but it also induces cellular and metabolic disorders that contribute to the functional impairment 11. Mechanisms of exercise-induced symptoms are multifactorial among which nociceptive pain 12, nerve dysfunction 13 and skeletal muscle abnormalities 11 are suggested.

Potential mechanistic drivers of exertional limb symptoms in addition to arterial obstruction and reduced perfusion include inflammation, vascular dysfunction, reduced microvascular flow, impaired angiogenesis, and altered skeletal muscle function 14-16 (Figure 1). A healthy vascular endothelium produces several vasodilator substances, including nitric oxide (NO), which has pluripotent vascular benefits such as platelet inhibition, smooth muscle cell proliferation inhibition, leukocyte adhesion prevention, and angiogenesis induction. Diminished NO bioactivity in the lower limbs prevents increased blood flow with exercise 11. Vascular dysfunction may also exacerbate the vasoconstrictive effects of catecholamines and limit flow-mediated dilation 17-20. Inadequate angiogenesis and collateral vessel formation may potentiate limb ischemia and serve as a mechanism driving functional impairment 21. Skeletal muscle ischemia may drive local inflammation, exacerbating symptoms and altering muscle metabolism 22-24.

Patients with PAD present impaired walking endurance 25, slower walking velocity 26-28, gait abnormalities 26,27,29-31, poorer muscle strength 32, and poorer balance 33,34 compared to individuals without PAD. They may also reduce their walking activity and total activity to avoid leg symptoms 35, and studies have shown a functional decline occurring over time 25,28,36.

**Vascular and functional assessment in PAD**

***Vascular assessment***

General assessment of CV risk factors should be performed prior to exercise training rehabilitation to improve preventive measures and reach preventive goals. Ankle-Brachial Index (ABI) should be assessed before starting a training programme to detect and diagnose PAD and assess disease severity (Figure 2) 3. The measurement of ABI after exercise is also important to further detect ankle pressure drop, as some patients may have leg symptoms on exercise while ABI can be ≥0.91 at rest. A post-exercise ankle systolic blood pressure drop >30mmHg or a post-exercise ABI decrease >20% should be considered for PAD diagnosis 37. In patients with media calcinosis (for example in patients with diabetes or chronic kidney disease) measurement of ABI might not be possible because the arteries cannot be compressed by the cuff. In these cases, toe brachial index (TBI) can be used as alternative assessment (the pathological threshold usually retained is <0.70) 3.

***Walking distance assessment***

Walking distance is considered an important clinical outcome both for patients and clinicians. Standardised exercise testing should be used for assessment of functional impairment in patients with PAD (Figure 2).

*Treadmill assessment***.** Treadmill testing should be performed with patients familiarised to the treadmill and under reproducible conditions (i.e. avoiding exercise and alcohol prior to assessment). Patients should be asked to walk until maximal levels of pain, lightly holding or not holding onto the treadmill. If the tests are stopped for reasons other than leg pain, then this should be recorded. Patients are asked to indicate the claudication pain score they reached during walking, especially the point at which pain begins, and recovery based on a five-point scale (0 = no pain, 1 = onset of pain, 2 = mild pain, 3 = moderate pain, 4 = severe/maximal pain) 38. Common treadmill protocols include constant-load (single-stage) or graded exercise testing 39,40. The latter is performed at constant speed varying the slope of the treadmill. Established graded protocols include the Gardner/Skinner (3.2 km/h and a 2% increase in slope every 2 minutes) or the Hiatt protocol (3.2 km/h and an increase in slope of 3.5% every 3 minutes). Constant-load treadmill tests are performed at a fixed speed of 2 to 4 km/h and fixed gradient of 10 to 12%. Constant-load protocols have poorer reliability both for pain-free walking distance (PFWD) and maximal walking distance (MWD) compared with graded protocols (coefficient of variance 30 and 45%, respectively) 41,42. Treadmill tests have limitations including learning effect during repeated evaluations. Also, some patients are unable or are unwilling to perform a treadmill test, mainly due to balance impairment or limited walking abilities.

*Six-minute Walk Test****.*** The six-minute walk test (6MWT) is performed along a flat corridor with a length of 30m with turning points marked by a cone. Patients are asked to walk self-paced for the full duration and may stop and rest at any point in the test 43. The total distance walked is measured and reported as the six-minute walking distance (6MWD) 43. Any encouragement given/phrases used should be the same for every test performed to ensure test-retest reliability 43. Further, there may be a learning effect so it is recommended that the best out of two walks is recorded or the first test discounted 44. Although treadmill-based exercise tests can establish maximum walking capacity, there may be a poor correlation between treadmill outcomes, habitual walking, and self-reported walking distance 45. On the other hand, compared to treadmill test, the 6MWT has been shown to better represent daily life walking in patients with PAD 46. The 6MWT is a well-validated and low-cost test. It has good reliability, with a correlation coefficient of 0.90 (p<0.001) and a coefficient of variation of 8.9% with testing performed one to two weeks apart 47. Changes in the 6MWT can be used to predict mortality and mobility loss in patients with PAD 7,48. The minimal detectable changes (i.e. the statistical detectability of change beyond measurement error) in the 6MWT are represented by a change >46 meters 49. The minimal clinically important difference (i.e. the clinical relevance or importance of the observed change from the patient's perspective) in the 6MWT in patients with PAD is represented by an improvement of 8 50 or 9 meters 51 for small changes, and 20 50 or 38 meters 51 for large changes.

*Connected Devices****.*** A measure of “real-life” walking performances may be performed by use of global positioning systems (GPS) or commercially available devices such as activity trackers, smart watches and phones 52. Research has shown that GPS recorders have good accuracy and reliability when compared to known distances walked 53,54, and measurement of step counts with mobile phones has been shown to be highly reliable even at low walking speeds 55. Further, GPS recorded walking distances correlate well with treadmill walking distances 56. Patients should be able to note the initial onset of claudication pain and the maximal walking distance either in total or between bouts of walking using the GPS system.

***Muscle strength assessment***

The presence of PAD is associated with impaired lower extremity muscle strength and function 57, which is associated with high prevalence of frailty and sarcopenia 58. Muscle strength and function should therefore be assessed before and after supervised exercise training (SET, Figure 2). There is heterogeneity in how muscle strength and function are assessed. Muscle isokinetic strength and endurance can be assessed via isokinetic dynamometry, which is a chair device that patients sit on and the specific joint is tested in an appropriate position with the dynamometer attached to the limb. Patients push against the dynamometer as it provides resistance to maintain a set speed. Isokinetic dynamometry has demonstrated good reliability at the ankle (reliability coefficients ranging from 0.77 to 0.96) 59. Testing can be done in various joints, including ankle, knee, and hip, in various planes such as extension and flexion. As isokinetic dynamometry assessment includes specialised equipment it may not be practical or convenient to assess patients using this device. As an alternative, the short physical performance battery (SPPB) which includes a 4-metre walk test, a sit-to-stand chair test, and a standing balance test, should be used 60. A recent study showed that the sit-to-stand is a validated test to estimate muscle power in patients with symptomatic PAD 61. Interestingly, muscle power assessed by the sit-to-stand test was related to overall functional performance prior and following SET 61.

***Self-reported functional impairment and quality of life assessment***

In addition to objective assessment of functional impairment, a subjective (self-reported) evaluation of walking abilities and health-related quality of life (HRQoL) should be incorporated to have a complete assessment of the functional status of the patient (Figure 2) 62-64. Following exercise interventions, assessing HRQoL is usually used to determine if an objective improvement in functional performance is also perceived by the patients in their daily life. Table 1 reports the most used subjective tools used for walking ability and HRQoL assessment in patients with PAD. Trials used a wide variety of questionnaires of patient reported outcomes measurements (PROMs) 62-64. The most used are the short-form health 36 (SF-36), a generic questionnaire including physical and mental items related to health), and the Walking Impairment Questionnaire (WIQ), a PAD-specific questionnaire focusing on PAD and functional limitations. Studies have shown that HRQoL burden is greater in magnitude in patients with both PAD and CVD than with CVD alone 65. In the PARTNERS study, the SF-36 Physical Component Summary of the combined PAD-other-CVD group was 46.3 ± 1.2 compared with 55.5 ± 1.1 in the other-CVD group 65. Cross-sectional studies show that in patients with PAD the degree of difficulty in walking distance and stair climbing are significantly related to HRQoL 66. The ESVS VASCUNET and the International Consortium of Vascular Registries consensus statement recommended the Vascular Quality of Life Questionnaire-6 (Vascu-QoL6) as a primary assessment of PROMs in patients with symptomatic PAD 62.

Greater amounts of physical activity are associated with higher ratings of both perceived health and HRQoL, correlating with objective health outcomes and life expectancy 67. One of the most important factors linked to both subjective and objective health, across both cognitive and physical domains, is physical activity 68.

**Exercise therapy in patients with PAD**

***Screening prior to exercise training participation***

All patients should be medically screened before SET programme initiation (Figure 2). It is suggested to include a complete medical history and examination 38. Patients with contraindications to exercise training (Table 2) should be excluded from SET until the relevant condition stabilises or is successfully treated. For patients with current or prior symptomatic cardiac disease (Table 3), we recommend that they are referred for cardiology work-up, including an exercise test to assess for evidence of exercise-induced coronary ischaemia, to identify if additional treatment for cardiac disease is required before proceeding with SET. Comorbidities (such as neurological and orthopedic diseases leading to gait abnormalities) should be documented and considered for how they may limit SET programme participation feasibility. After SET programme initiation, patients should continue to be closely monitored for changes in health status (e.g., any symptom or situation which may suspect undiagnosed/incident cardiac condition, ischemic limb pain at rest, toe or foot wounds) that might necessitate interruption of the programme, at least temporarily.

***Supervised exercise training***

SET is considered among first-line therapies for patients with chronic and symptomatic PAD (Figure 2) 3,64,69,70. SET is safe and is usually conducted in the hospital setting 71. Over the past 60 years, many trials have reported the effectiveness of SET on walking distances in these patients 72,73. The most recent Cochrane meta-analysis showed that SET improves PFWD (82 m; 95% IC: 72 – 92) and MWD (120 m; 95% IC 51 – 190) 74. Similar findings were observed in another meta-analysis [PFWD: 128 m (95% IC: 92 – 165); MWD: 180 m (95% IC: 130 – 238)] 75. Although less well investigated or usually reported as a secondary outcome, SET also improved functional status, gait pattern, self-reported walking ability and quality of life 64,74,76-82. It is interesting to note that cardiac rehabilitation programmes also increase walking distance, HRQoL, and physical activity in patients with symptomatic PAD, suggesting that other types of rehabilitation than SET may also be useful 83. Finally, some vasoactive drugs such as cilostazol (phosphodiesterase type 3 inhibitor), pentoxifylline (xanthine derivative), bosentan, sildenafil and others are claimed to increase walking capacity in patients with PAD 84-87. However, the objective documentation of their effect is very limited to draw extensive conclusions 84,88. More studies are needed to confirm additive effect of drug therapies to supervised exercise.

*Training modalities.*There are different types of exercise training for patients with PAD, but the common aim is to improve walking capacity and reduce symptoms. In addition, exercise should aim to improve balance and muscle strength to promote independence and a reduced risk of falling in the long-term 33. Treadmill and overground walking are the most common and recommended training modalities in patients with IC (Figure 2) 64,70. However, due to severe exercise-induced ischemia, low pain tolerance, the risk of falling and/or other co-morbidities, some patients are unwilling or unable to perform walking sessions. In addition to walking training, there are several other forms of training that are used, although much less frequently, in the rehabilitation of patients with PAD. A recent meta-analysis reported that other non-walking training modes are also effective as traditional walking training in improving walking performance, whereas there was no clear evidence for changes in quality of life following exercise interventions. However, the authors concluded that the certainty of this evidence was judged to be low 89. Different training modes include strength training of large muscle groups 90,91, cycling 92, pole striding 93,94, multimodal training 76,77,95-98 and training with an arm-crank ergometer 99,100. The beneficial effect of these training modalities can usually be described as large and even reach those of typical walking training 101. However, the PFWD and the MWD have the tendency to be higher with walking training than with strength training when all studies are considered 89. In contrast, self-reported ability to climb stairs (assessed by the Walking Impairment Questionnaire) is more improved following strength training (29.2% vs. 43.8% after 6 months) compared to walking training on the treadmill (39.6% vs. 43.8% after 6 months) 102. Therefore, when walking is not an option, alternative training modalities might also be effective. These training modalities also elicit lower or no pain during exertion compared to walking, which might lead to higher rates of adherence.

*Training frequency.*Based on a previous meta-analysis, and shared by most of the studies and guidelines, the training frequency associated with greater improvements in walking distance is at least 3 times per week 103,104.

*Training duration.*Identifying an optimal training duration is difficult to elucidate, mainly due to differences in training modalities, frequencies, and intensities among studies. Current guidelines reported that optimal training duration ranges between 12 and 24 weeks 64,70,103. The optimal training session duration has not been widely investigated. Additionally, in most studies, the total session duration is usually reported without specifying the actual time spent exercising. The literature shows that exercise sessions lasting 30 to 60 min were the most effective to improve walking performance 103,104.

*Training intensity.*In most studies, no clear distinction is made between symptom intensity (claudication pain scale) and exercise training intensity [based on heart rate (HR), oxygen uptake () or rate of perceived exertion (RPE) on Borg’s scale: 6: “very very light”; 20: “maximal effort”] to monitor the exercise therapy. The Borg scale is a subjective assessment tool used to measure an individual's perceived exertion or effort during physical activity. The scale assigns a numerical rating ranging from 6 to 20 to indicate the intensity of exertion experienced by the person 105.

First, the majority of trials used claudication pain severity to provide guidance during the training sessions. In PAD research, the claudication pain scale, an ordinal scale from 0 (no pain) to 4 (severe/maximal pain), is the most commonly used tool. A distinction is made between walking training with and without muscle pain caused by ischemia. With regards to claudication pain intensity, international guidelines are heterogeneous 38,64,70. The UK NICE guideline encourages patients to exercise to the point of maximal pain , the American Heart Association guideline recommends moderate to moderate/severe claudication pain as tolerated 64, while an international consensus as well as the Australian guideline does not specify pain intensity for exercise dosage 106. Based on strong evidence 64,73-75,104, the current consensus is that patients should exercise to moderate-high claudication pain to improve walking performance. Also, one-year home-based walking training performed at high-intensity pain has been found to be more effective than walking training performed at low-intensity for improving walking and functional performance in patients with PAD 107,108. These findings indicate that claudication pain intensity may be a key factor for walking improvement in these individuals. In contrast, others have reported that improvements in walking performance may be obtained with less severe claudication pain during exertion 101. According with recent findings, walking training with pain is not clearly superior to walking training without pain regarding changes in walking distances 109-112. It may be assumed that walking training with moderate, low, or no pain is associated with higher compliance and possibly long-term maintenance of training or change in activity behaviour 112. This indicates that a more flexible approach to exercise prescription may therefore be required, considering the patient’s needs and preferences, and what might achieve a high level of (long term) adherence. Larger studies with a higher number of cases and longer duration, taking compliance into account, are needed for a conclusive statement 113.

Second, the optimal no/low pain-based exercise training intensity is understudied in this population. Indeed, it is interesting to note that the claudication pain severity does not necessarily rely on common measures of exercise intensity 78,114. For example, when performing vigorous-intensity exercise, some patients may experience moderate-to-severe claudication pain, whereas others, low levels of claudication only. Assuming that exercise intensity is a cornerstone determinant of physiological response to training 115, monitoring claudication pain only is limiting and prevents accurate comparison of exercise effectiveness in patients with PAD. This may also explain the large variability in the magnitude of improvements following exercise interventions 64,103. Fassora et al. 78 recently reported that both training modality and exercise intensity should be considered when looking for the best results in walking performance and cardiorespiratory fitness. Notably, these results showed that walking at vigorous intensity (%HRpeak: 77-95, %: 64-90, RPE: ≥ 14 115) induced the greatest improvement in MWD, while cycling and other non-walking modalities performed at vigorous intensity elicited the greatest improvements in cardiorespiratory fitness 78. These findings suggest that both walking and cardiorespiratory capacities are desirable outcomes but that they need different exercise therapy programmes 78. It is however important to note that training programmes should start with a lead-in period performed at low-to-moderate exercise intensity and, if tolerated, gradually progressed to vigorous exercise intensity. This approach may allow to determine the patient’s exercise response and tolerance, reducing the risk of complications.

The monitoring of the exercise intensity during a resistance training program is mediated by the percentage of the one repetition maximum (1RM) 116. The determination of the 1RM plays a key role to objectively set an individualised resistance-based program 116. Compared to a direct assessment of the 1RM, the multiple RM assessment (such as 10RM, the maximum weight a person can lift for 10 repetitions) is considered to be a safe and well tolerated approach to evaluate muscle strength for a given muscle group in patients with cardiovascular diseases 116. Following the multiple RM test, different prediction equations are available to estimate the 1RM 117. As also used in the cardiac rehabilitation, a target exercise intensity of 30-70% of 1RM for the upper body, and 40–80% of 1RM for the lower body should be considered 117. Exercise intensity should be progressively increased to determine the patient’s exercise response and exercise tolerance. It has been shown that resistance training improves walking performance and muscular strength in patients with PAD 118. Notably, high intensity (i.e. 80% 1RM) induces the best improvements in walking performance when compared to low-to-moderate (i.e. <50% 1RM) strength training intensity in these patients 90,118.

Table 4 summarises the main exercise prescription recommendations with some practical applications.

***Home-based exercise training***

In comparison with patients not undergoing exercise training, a home-based training (HBT) strategy resulted in a non-significant increase of MWD in a recent meta-analysis (mean difference: 136 m; 95% CI: -2 to 273 m; p = 0.05) 119. When comparing HBT with basic exercise advice, no improvement of MWD was observed in patients following a HBT strategy (mean difference: 39 m; 95% CI: -123.1 to 201.1 m; p = 0.64) 119. Regarding PFWD, HBT led to a greater increase than exercise advice did (mean difference: 64.5 m; 95% CI: 14.1 to 114.8 m; p = 0.01) 119. In comparison with HBT, SET was more effective in improving MWD (mean difference: 139 m; 95% CI: 45 to 232 m; p = 0.004) and PFWD (mean difference: 84 m; 95% CI: 25 to 143 m; p = 0.005) 119.

Considering the effect of monitoring in HBT, no difference in the change of MWD and PFWD were observed between monitored HBT and SET (mean difference in MWD: 8 m; 95% CI: -81 to 97 m; p = 0.86; mean difference in PFWD: 43 m; 95% CI: -29 to 114 m; p = 0.24) 119. The equality in training efficacy of monitored HBT and SET emphasises the role of monitoring in HBT programmes. Apart from regular on-site visits or phone calls, activity diaries or log books have been used for HBT monitoring 119. Additional tools for self-monitoring, such as wrist-worn activity trackers with smartwatch-like functions or smartphone accelerometer applications have been assessed, however, it still needs to be clarified, which modality is most appropriate 55.

The effect of training on patients’ daily physical activity was assessed by several studies implementing pedometer- and accelerometer-measurements. A network meta-analysis demonstrated improvements of daily physical activity in HBT to a similar extent as it was observed in patients undergoing SET 120.

Focusing on quality of life, most studies reported improvements in patients undergoing HBT 119. In comparison with SET, improvements of individual SF-36 measures (pain and social functioning) and Walking Impairment Questionnaire measures (distance) were less pronounced in patients undergoing HBT 119. In addition, HBT improves measures of self-efficacy for walking, satisfaction with functioning, pain acceptance and social functioning in patients with claudication 121. Follow-up data of patients who had undergone HBT suggest sustained improvements in measures of quality of life, functional and walking capacity after termination of the active training intervention 122,123.

Safety of HBT was analysed in a systematic review including 27 studies, which reported a cardiac event rate of 1 per 49,270 and a non-cardiac event rate of one per 147,810 124. Event rates of HBT were lower than event rates reported for SET (HBT vs. SET: cardiac 1:49,270 vs. 1:13,788; non-cardiac: 1:147,810 vs. 1:41,363) 124. Regarding overall mortality, retrospective data suggest a reduction of long-term mortality in patients undergoing HBT 125. Comparing HBT with SET, overall mortality rates do not differ between patients undergoing HBT and patients following a SET programme 126. The results of the reported meta-analyses and reviews should be viewed with caution according to a moderate to low quality of evidence 119,126,127. Due to the limited availability and utilisation of SET programmes, HBT programmes can be used as a valid alternative training modality for patients with IC 128-131.

Data on sex-specific differences in the efficacy of HBT are inconsistent 132,133. In females, the efficacy of HBT appears to be more strongly related to the individual training intensity than in males 134. Regarding co-morbidities, HBT seems to be less effective in patients with diabetes with respect to the potential increase in walking capacity 135. In elderly patients, HBT potentially improves quality of life to a similar extent as revascularisation does 136. Considering the frequency of HBT training, 3 weekly sessions was the most commonly training strategy (range: 3 weekly sessions to daily sessions) 119. For initiation, patients should start with a duration of 20 minutes per session, progressively increasing the duration to 60 minutes per session. HBT can be performed outside, around a track or in a hallway at a self-selected pace 51,137.

***Long-term adherence to exercise therapy***

In clinical practice, long-term adherence to therapy is a major problem. Participating in SET programmes may help patients to acquire awareness of the disease and learn the importance of exercise and how to practice it. SET programmes can be regarded as a transition phase to improve self-management and may serve as a bridge for those patients that need it to other forms of exercise approach such as community or home-based exercise. Telemedical monitoring through step counting with pedometers or activity monitors proved to be effective 138,139, as did supervised structured walking exercise to improve pain-free and maximal walking distance 119. In addition to monitoring, factors such as education, self-efficacy, goal setting, feedback, and a training plan were critical to successful outcomes 119. This should be used more frequently in clinical practice to increase long-term adherence but needs to be demonstrated in long-term studies.

**Mechanisms of response to exercise in PAD**

Exercise represents a major challenge to whole-body homeostasis provoking widespread perturbations in numerous cells, tissues, and organs that are caused by or are in response to the increased bio-energetic activity of the contracting skeletal musculature 140. The exercise training-induced increase in functional capacity and the concomitant amelioration of diverse maladaptive responses that ultimately reduce claudication symptoms in patients with PAD, are underpinned by several inter-dependent physiological, metabolic, and mechanical mechanisms. After several months of exercise training there is extensive remodelling of the vascular system, and although direct sampling of the vasculature in humans *in vivo* is limited, the trained musculature provides a valid proxy, being the primary tissue involved in training adaptation 140. The dynamic biochemical and mechanical environment around blood vessels arising from the forces provoked during skeletal muscle contractile activity (i.e., shear stress and passive stretch), as well as signals stimulated by the increases in muscle energetic demand (i.e., increases in AMP concentration, reduced oxygen delivery) activate several intracellular signalling pathways responsible for promoting a regulatory network governing the transcriptional control of mitochondrial biogenesis and respiratory function along with enhanced expression of pro-angiogenic factors 141 (Figure 3).

Over time, this results in the initiation of capillary growth and a proliferation in the number of arterioles. Such structural remodelling is driven by a complex and often-redundant sequence of events that include NO, and prostaglandins. Indeed, mechanical, neural, and humoral factors, including those released from contracting skeletal muscle, have all been implicated in the remodelling response, with the vascular endothelial growth factor (VEGF) signalling pathway and downstream targets ultimately driving skeletal muscle capillary expansion 141. Muscle activity increases VEGF in the muscle interstitium and subsequently acts on the VEGF receptors, VEGFR-1 and VEGFR-2 on the capillary endothelium, activating multiple downstream pathways via signalling intermediates such as mitogen activated protein kinases (MAPK), phosphatidylinositol-3-Kinase 142. The time-course of remodelling varies and is largely a function of the blood vessel size, and while many of these adaptations are restricted to the vascular beds of the trained muscles, improved endothelial function appears to be a whole-body response to exercise training, even in individuals with PAD.

VEGF expression is partially regulated by the hypoxia-inducible factor-1 (HIF-1) but recently the peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) has emerged as an important candidate in the exercise-induced angiogenic response. PGC-1 regulates the coordinated expression of mitochondrial proteins encoded in the nuclear and mitochondrial genomes and is rapidly induced after exercise. This protein has been called the “master regulator” of mitochondrial biogenesis, and controls various aspects of muscle oxidative phenotype, while transducing and integrating physiological signals governing metabolism, differentiation, and cell growth, and suppressing a broad inflammatory response 143. Thus, the PGC-1 coactivators serve as a central component of the transcriptional regulatory circuitry that coordinates the energy-generating functions of mitochondria in accordance with the metabolic demands imposed by exercise training undertaken by patients with PAD.

**Exercise and revascularisation**

Current guidelines recommend SET programmes as an initial treatment modality for patients with IC 3,144. Revascularisation is recommended for patients with IC when they do not respond to initial exercise and medical therapies 145. However, the role of revascularisation as an initial treatment option alone or as an upstream adjunct to SET in patients with IC remains controversial.

Several trials have compared endovascular therapies with or without SET versus SET alone as an initial treatment strategy for patients with PAD with IC and reported inconsistent results 146-149.

The relevant aspect of exercise training may be the reduction of the inflammatory process in patients with PAD. In a recent trial, reactive oxygen species (ROS) formation was measured using the luminol analogue L-012 for patients with IC, randomised either to home-based training alone or in addition to endovascular therapy (EVT) 150. Follow-up was performed after 3 months. ROS production after NOX2 (NAPDH oxidase 2) stimulation showed a significant reduction in both groups at follow-up (EVT group: p = 0.002, exercise group: p = 0.019), with a higher relative reduction in ROS in the EVT group than in the exercise group (p = 0.014).

The data regarding the benefit of SET alone or in combination with EVT or EVT alone are rare. A robust evaluation of existing data comes from a meta-analysis comparing the different treatment approaches 151. A total of 987 patients from 7 randomized control trials (constituting 9 total comparison arms) with a median follow-up duration of 12.4 months (range 10 to 18 months) were enrolled. Of these, 530 patients were randomized to EVT versus SET alone, and 457 patients to EVT plus SET versus SET alone 151. For the effect of EVT alone versus SET alone (5 comparison arms) a random effects model showed no significant difference in the MWD (standardised mean difference (SMD): -0.11 (95% CI: -0.59 to 0.36); p = 0.64) on follow-up between the 2 groups, neither for the PFWD, need for revascularisation or amputation. On pooled analysis, the ABI was significantly higher among participants that underwent EVT alone as compared with SET only (SMD: 0.64; 95% CI: 0.38 to 0.90, p < 0.0001; weighted mean difference (WMD): 0.15; 95% CI: 0.10 to 0.19, p < 0.0001).

On pooled analysis using random effects models, EVT plus SET (4 comparison arms) was associated with significantly higher MWD on follow-up compared with SET alone (SMD: 0.79; 95% CI: 0.18 to 1.39, p = 0.01), as well as significantly higher ABI on follow-up compared with SET only (SMD: 0.62; 95% CI: 0.33 to 0.91; WMD: 0.14; 95% CI: 0.10 to 0.17, P < 0.0001).

The combination of EVT plus SET was also associated with a significantly lower risk of revascularisation or amputation on follow-up (3.5% vs. 17.3%, OR: 0.19; 95% CI: 0.09 to 0.40, P < 0.0001). The corresponding number needed to treat was 8 patients (95% CI: 6 to 12). PFWD was reported in 2 studies with no difference between the 2 groups in random effects pooled analysis 151. However, EVT alone is not associated with better outcomes than SET 151,152. Among patients with stable PAD and IC, compared with SET alone, endovascular revascularisation in combination with SET is associated with improved outcomes.

Exercise training after surgical revascularisation also improves outcomes compared to revascularisation without exercise training. Although much less investigated, few publications exist on the impact of exercise on the outcome after surgical revascularisation of symptomatic PAD. One small RCT compared patients after bypass surgery (n=14) 153. Group I had standard preoperative and postoperative care and the intervention group (group II) had SET 4-10 weeks postoperatively. MWD, mean increase in ABI and improvement in WIQ were significantly better in group II. In another recent study, patients who underwent above knee femoropopliteal bypass were divided into two groups: those who continued regular exercise after bypass operation with those who discontinued exercise after surgery 154. After propensity score matching, 5-year primary and secondary patency (PP: 97% vs. 61%, p = 0.0041; SP: 100% vs. 69%, p = 0.0021), and freedom from major adverse cardiovascular events (61% vs. 24%, p = 0.0071) were significantly better in patients who continued exercise. One systematic review included all RCTs with either surgical or endovascular revascularisation to evaluate the evidence on the efficacy of lower limb revascularisation combined with supervised exercise training in patients with PAD 155. Eight trials with 726 patients showed that combined therapy led to greater improvements in PFWD and MWD compared with revascularisation or supervised training alone. In 2 out of 8 studies, revascularisation was surgical and in 6 studies it was endovascular.

**Effect of exercise on health-related quality of life and cognitive function**

Poor HRQoL is associated with higher rate of mortality in patients with PAD 156. Randomised controlled trials have shown that exercise training versus usual medical care in patients with PAD not only improves the perceived walking distance and speed, but also the functional status as measured by specific impairment questionnaires, as the WIQ. When compared to controls, patients who complete any form of exercise training significantly improve their WIQ speed (mean difference: 9.60; 95% CI: 6.98 to 12.23, p ≤ 0.001); WIQ distance (mean difference: 7.41; 95% CI: 4.49 to 10.33, p ≤ 0.001) and WIQ stair-climbing (mean difference: 5.07; 95% CI: 3.16 to 6.99, p ≤ 0.001) 80. In addition, more general HRQoL evaluation scores (Short-Form Physical Component Summary) also showed significant improvement following exercise therapy (mean difference: 1.24; 95% CI: 0.48 to 2.01) 80. Most of the studies showed that 3- 157-159, or 6/12-month 94,102,160 exercise training improves patient’s perception of physical HRQoL, with lesser effects on mental HRQoL. However, in the current literature, findings are inconsistent 74,80,161 and other studies did not find the same effects 162-164. It is interesting to note that the improvement in general HRQoL scores (as SF-36) were mainly predicted by physical functional markers, such as the distance covered during a 6MWT (6MWD) and the history of stumbling 165. These data indicate that greater improvements in physical function following exercise therapy are expected to have greater improvements in self-perceived HRQoL 165. It has recently been showed that improvements in 6MWD following SET are predictive of augmentations in general HRQoL in patients with PAD 96. Interestingly, changes in treadmill performance, which are less representative of functional walking 46, were not related to improvements in HRQoL 96.

Regular physical activity is also known to improve cognitive functioning and brain health across the lifespan 166. Cross-sectional and experimental studies show that greater amounts of physical activity are linked to better cognitive function in adults, with the best performances for exercise programmes that are structured, individualised, higher intensity, longer duration, and multicomponent 167. These results support a dose-dependent neuroprotective relationship between physical exercise and cognitive performance. Physical exercise interventions aimed at improving brain health through neuroprotective mechanisms show promise for preserving cognitive performance 167. Scientific evidence based on functional and neuroimaging approach has demonstrated that this relation could be mediated by improved brain integrity, including adaptations in cerebral blood flow, volume and white matter integrity 168.

**Patient education**

All patients with PAD should be offered oral and written information about their disease so they can share decision-making and understand what they can do to help manage their condition. The role of exercise should be clearly explained, and patients should be supported to exercise regularly (assuming no contraindications). The impact of patient education regarding exercise is probably dependent on several factors, including the specific information that is provided, the timing and mode of delivery, and the nature of any interventions that are delivered concomitantly (e.g., SET). Patient education in the form of brief exercise advice, when delivered in isolation, confers little benefit and results in minimal improvement in individuals’ walking distances 169. Structured education programmes, on the other hand, may have greater potential to improve exercise behaviour and walking distances by building the knowledge and skills of patients to enable them to successfully self-manage their condition 170. Key programme features include: a structured evidence-based curriculum that includes content on the nature of the condition and the role of exercise; delivery by trained educators; and embedded quality assurance processes 170.

A systematic review by Abaraogu et al. 170 identified six studies (1,087 participants) that had investigated the effects of structured education for patients with PAD and IC. The interventions varied widely, but all included education sessions, exercise prescription, and behaviour change techniques. Four trials reported improvements in walking ability in intervention versus control comparisons 170. Effects on physical activity and quality of life were mixed. Overall, the evidence was inconclusive and more rigorous trials are needed that include a clear and complete description of the education intervention. Participant feedback from three studies highlights intervention features that may be important for improving physical activity: providing information about PAD/IC and exercise; providing encouragement and support with self-monitoring; and having group interaction while allowing space for individual discussion 170.

Three other trials have tested exercise programmes that had an educational component in patients with PAD 171-173. The GOALS trial 172 randomized 194 participants either to a group-mediated cognitive behavioural intervention or an attention control group. The intervention consisted of group meetings with a facilitator once weekly for 6 months. Discussion topics included effective behaviour change methods, self-monitoring, exercising in cold weather, managing leg pain during exercise, and overcoming other obstacles to exercise adherence. At the 6-month follow-up, the intervention group achieved a 53.5 meters greater increase in 6MWD compared with the control group. Next, the HONOR trial 173 tested the efficacy of telephone coaching combined with a wearable activity monitor and showed no improvement in 6MWD at the 9-month follow-up. Finally, the MOSAIC trial explored the effect of a physiotherapist-delivered motivational interviewing intervention in 190 patients with PAD and IC 171. A statistically significant mean difference of 16.7 m in 6MWD was observed at 3 months follow-up compared with usual care control 171. The contrasting results of these trials indicate that exercise programmes that include education are more likely to be successful if they include periodic visits to a medical centre to meet with a coach or include tailored behaviour change components.

**Sex and exercise**

Prevalence of PAD in women is similar to men at all ages 174,175. However, women are more likely to have asymptomatic PAD and less likely to report IC 176. Decreased detection and subsequent intervention may then result in a higher proportion of women with severe disease and chronic limb-threatening ischemia. Further, women who undergo revascularisation tend to be older and have more severe PAD compared to men, and these factors can affect outcomes of procedures adversely 177. Contradictory results exist on women with PAD and mortality rates 178-180. Population studies suggest a trend towards higher mortality rates in women with lower ABI 179.

Exercise performance has been used to suggest that women decline faster in terms of functional ability once PAD is established. However, this difference may in fact merely be due to the smaller muscles in the calves of women 181. McDermott et al. 182 showed that at 4 years of follow-up, women were more likely to become unable to walk for 6 min continuously than men, more likely to develop mobility disability, had faster declines in walking velocity, and the distance achieved in the 6MWT was less. However, these apparent sex differences in functional decline were attenuated after additional adjustment for baseline calf muscle area, and so may be attributable to smaller baseline calf muscle area in women. Interestingly poorer leg strength is associated with increased mortality in men, but not in women, with PAD 181.

The data on the efficacy of exercise rehabilitation in women with PAD compared to men are scarce. What is known, however, is that women with IC seem to have a poorer response to exercise rehabilitation, smaller changes in PFWD and MWD following three months of exercise than men (Δ 280 meters for men vs Δ 220 meters for women; p = 0.04) 183. This is particularly so in those with diabetes 132. Reduced blood volume expansion and slower oxygen kinetics occur in the calf musculature during exercise in women with PAD with IC 184. Further, recent data showed that this poor response to exercise in women with IC and diabetes was not related to where the intervention was performed, being impaired both in a supervised exercise class and a home exercise setting 132. This poorer response to exercise was also demonstrated in the EXITPAD study, which showed that women with IC, independent of confounding factors including diabetes, benefit less from supervised exercise and have significantly lower MWD after 12 months. Higher level of metabolic syndrome presents in postmenopausal women compared with similarly aged men, may contribute to this 183. On the contrary, it has recently been shown that multimodal SET (combining strengthening of lower limbs and Nordic walking) significantly improves walking performance (treadmill and overground) in women and men, with no difference between groups 98,185. Although not significant, it is interesting to note that women had greater improvements (i.e., delta) than men 98.

The clinical implication is that women with IC may respond less well to current exercise interventions and either need a greater ‘dose’ of exercise, or another intervention separate or in combination with exercise, to obtain similar improvements in IC as that seen in men with exercise alone.

**Situation in Europe**

Despite of the large body of evidence highlighting benefits, SET is underused, and its availability and adherence is low 128-130,186-192. To note, the rate of clinicians referred a patient for SET in very low 128. The reasons and barriers for not participating in SET programmes are lack of facilities, feeling worse, costs, time, lack of motivation, and comorbidities 128,130,187.

The situation with SET in Europe varies from country to country. A recent European survey showed that supervised exercise programmes exist in Austria, Belgium, Czech Republic. France, Germany, Italy, Sweden, Switzerland, and United Kingdom 193. However, SET is reimbursed by the health insurance only in Austria, Belgium, France, Germany, Sweden, and Switzerland 193. In the United Kingdom, SET programmes are funded by the National Health Service. In contrast, SET is not reimbursed in Czech Republic, Italy, and it even does not exist for patients with PAD in Denmark, Greece, Ireland, Poland, Serbia, Slovakia, Slovenia, or Ukraine 193. Similarly, the structured home-based exercise programme is not routinely present in European countries 193.

Importantly, there is heterogeneity in form of SET in most of individual countries, with existence of individual programmes or practice of each hospital or community 193. They differ in respect of frequency, length and duration of training, type of exercise, as well as by supervising professional 193. Mostly, the SET is coordinated by angiologist/vascular physician, but sessions are predominantly supervised by clinical exercise physiologists or physiotherapists. SET for patients with PAD is sometimes offered in cardiac rehabilitation centres. Training programme duration is mostly 12 weeks or less, with session duration 30-60 min. Most often used training modalities are combination of walking and resistance training or walking training alone 193.

To standardise SET programmes and provision across Europe, the following steps are required: 1) a more widespread availability of SET programmes and standardised outcomes to assess their effectiveness; 2) a more defined harmonisation of SET characteristics (establish process of referral, supervision, coordination, selection of patients, SET protocols); 3) health insurance reimbursement of costs; and 4) action to improve the public knowledge about the benefits of SET 193.

**Gaps in evidence and further studies**

Awareness and access to supervised exercise programmes should be a field of further studies. Additionally, there are still many areas of insufficient or inconsistent evidence in the treatment of claudication with exercise therapy. We do not know the optimal therapy in terms of duration of the single walking session or intensity of training. We have few studies on the impact of no, or low pain-based exercise and the data on sex differences are inconsistent. The combination of walking exercise with non-walking training has not been yet established. Also, we need more evidence to better understand the potential role of wearable monitoring during exercise interventions, and to evaluate on the efficacy of supportive interventions that can be used together with exercise therapy. For example, the effect of different hydration strategies used during exercise training needs more evidence. In a non-randomised study, Parodi et al. reported mean increase in treadmill walking from 100 meters to 535 meters in 131 patients, who were treated with hydration, determined as drinking at least 2000 mL of water during 24 hours for a period of 6 months and to ingest albumin and salt (3.5 g/day) 194.

Moreover, data on the interference of exercise training, as well as of individual training modalities, with medical treatment in patients with IC is scarce: one historic RCT suggested an augmentation of the beneficial effect of exercise training by antiplatelet therapy 195. Another more recent RCT suggested an additive effect of cilostazol on top of exercise treatment on absolute claudication distance 196. However, it needs to be taken into account that both studies had very small sample sizes. Therefore, larger prospective trials are needed to further elucidate the interaction between exercise training and medication in PAD.

Another area of future research should be exploration of the best modalities to transition patients from supervised exercise programmes to everyday life while maintaining the beneficial effects. Finally, we need more research on how to measure success in exercise training in an accurate and reproducible way.

**APPOINTED REVIEWERS**

Vinko Boc (Department of Vascular Diseases, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia); Tristan Mirault (Université Paris Cité, Inserm, PARCC, F-75015, Paris, France; Service de médecine vasculaire, Hopital Européen G. Pompidou, Paris, France); Frederico Bastos Gonçalves (Department of Angiology and Vascular Surgery, Hospital de Santa Marta, Centro Hospitalar de Lisboa Central, Lisbon, Portugal); Christian-Alexander Behrendt (Department of Vascular Medicine, University Heart and Vascular Centre UKE Hamburg, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany).

**References**

1. Pelliccia A, Sharma S, Gati S, Back M, Borjesson M, Caselli S, et al. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. *Eur Heart J* 2021;42:17-96. 10.1093/eurheartj/ehaa605

2. Song P, Rudan D, Zhu Y, Fowkes FJI, Rahimi K, Fowkes FGR, et al. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. *Lancet Glob Health* 2019;7:e1020-e30. 10.1016/S2214-109X(19)30255-4

3. Aboyans V, Ricco JB, Bartelink MEL, Bjorck M, Brodmann M, Cohnert T, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). *Eur Heart J* 2018;39:763-816. 10.1093/eurheartj/ehx095

4. Frank U, Nikol S, Belch J, Boc V, Brodmann M, Carpentier PH, et al. ESVM Guideline on peripheral arterial disease. *Vasa* 2019;48:1-79. 10.1024/0301-1526/a000834

5. McDermott MM. Lower extremity manifestations of peripheral artery disease: the pathophysiologic and functional implications of leg ischemia. *Circ Res* 2015;116:1540-50. 10.1161/CIRCRESAHA.114.303517

6. McDermott MM, Greenland P, Liu K, Guralnik JM, Celic L, Criqui MH, et al. The ankle brachial index is associated with leg function and physical activity: the Walking and Leg Circulation Study. *Ann Intern Med* 2002;136:873-83.

7. McDermott MM, Liu K, Ferrucci L, Tian L, Guralnik JM, Liao Y, et al. Decline in functional performance predicts later increased mobility loss and mortality in peripheral arterial disease. *J Am Coll Cardiol* 2011;57:962-70. 10.1016/j.jacc.2010.09.053

8. Weitz JI, Byrne J, Clagett GP, Farkouh ME, Porter JM, Sackett DL, et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. *Circulation* 1996;94:3026-49. 10.1161/01.cir.94.11.3026

9. Rose GA. The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. *Bull World Health Organ* 1962;27:645-58.

10. McDermott MM, Mehta S, Greenland P. Exertional leg symptoms other than intermittent claudication are common in peripheral arterial disease. *Arch Intern Med* 1999;159:387-92. 10.1001/archinte.159.4.387

11. Hiatt WR, Armstrong EJ, Larson CJ, Brass EP. Pathogenesis of the limb manifestations and exercise limitations in peripheral artery disease. *Circ Res* 2015;116:1527-39. 10.1161/CIRCRESAHA.116.303566

12. Seretny M, Colvin LA. Pain management in patients with vascular disease. *Br J Anaesth* 2016;117 Suppl 2:ii95-ii106. 10.1093/bja/aew212

13. Tew GA, Ouedraogo N, Nicolas G, Leftheriotis G, Copeland RJ, Abraham P. Impaired somatosensation in patients with isolated proximal-without-distal exercise-related lower-limb ischemia. *Clin J Pain* 2012;28:404-9. 10.1097/AJP.0b013e3182340c01

14. Hammad TA, Strefling JA, Zellers PR, Reed GW, Venkatachalam S, Lowry AM, et al. The Effect of Post-Exercise Ankle-Brachial Index on Lower Extremity Revascularization. *JACC Cardiovasc Interv* 2015;8:1238-44. 10.1016/j.jcin.2015.04.021

15. McDermott MM, Dayanidhi S, Kosmac K, Saini S, Slysz J, Leeuwenburgh C, et al. Walking Exercise Therapy Effects on Lower Extremity Skeletal Muscle in Peripheral Artery Disease. *Circ Res* 2021;128:1851-67. 10.1161/CIRCRESAHA.121.318242

16. Sheikh MA, Bhatt DL, Li J, Lin S, Bartholomew JR. Usefulness of postexercise ankle-brachial index to predict all-cause mortality. *Am J Cardiol* 2011;107:778-82. 10.1016/j.amjcard.2010.10.060

17. Flammer AJ, Anderson T, Celermajer DS, Creager MA, Deanfield J, Ganz P, et al. The assessment of endothelial function: from research into clinical practice. *Circulation* 2012;126:753-67. 10.1161/CIRCULATIONAHA.112.093245

18. Gokce N, Vita JA, Bader DS, Sherman DL, Hunter LM, Holbrook M, et al. Effect of exercise on upper and lower extremity endothelial function in patients with coronary artery disease. *Am J Cardiol* 2002;90:124-7. 10.1016/s0002-9149(02)02433-5

19. Meredith IT, Currie KE, Anderson TJ, Roddy MA, Ganz P, Creager MA. Postischemic vasodilation in human forearm is dependent on endothelium-derived nitric oxide. *Am J Physiol* 1996;270:H1435-40. 10.1152/ajpheart.1996.270.4.H1435

20. Vita JA, Hamburg NM. Does endothelial dysfunction contribute to the clinical status of patients with peripheral arterial disease? *Can J Cardiol* 2010;26 Suppl A:45A-50A. 10.1016/s0828-282x(10)71062-x

21. Robbins JL, Jones WS, Duscha BD, Allen JD, Kraus WE, Regensteiner JG, et al. Relationship between leg muscle capillary density and peak hyperemic blood flow with endurance capacity in peripheral artery disease. *J Appl Physiol (1985)* 2011;111:81-6. 10.1152/japplphysiol.00141.2011

22. Beckman JA, Preis O, Ridker PM, Gerhard-Herman M. Comparison of usefulness of inflammatory markers in patients with versus without peripheral arterial disease in predicting adverse cardiovascular outcomes (myocardial infarction, stroke, and death). *Am J Cardiol* 2005;96:1374-8. 10.1016/j.amjcard.2005.07.041

23. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. *Circulation* 2005;112:976-83. 10.1161/CIRCULATIONAHA.104.513085

24. Vidula H, Tian L, Liu K, Criqui MH, Ferrucci L, Pearce WH, et al. Biomarkers of inflammation and thrombosis as predictors of near-term mortality in patients with peripheral arterial disease: a cohort study. *Ann Intern Med* 2008;148:85-93. 10.7326/0003-4819-148-2-200801150-00003

25. McDermott MM, Ferrucci L, Liu K, Guralnik JM, Tian L, Liao Y, et al. Leg symptom categories and rates of mobility decline in peripheral arterial disease. *J Am Geriatr Soc* 2010;58:1256-62. 10.1111/j.1532-5415.2010.02941.x

26. Gardner AW, Forrester L, Smith GV. Altered gait profile in subjects with peripheral arterial disease. *Vasc Med* 2001;6:31-4.

27. Gommans LNM, Smid AT, Scheltinga MRM, Cancrinus E, Brooijmans FAM, Meijer K, et al. Prolonged stance phase during walking in intermittent claudication. *J Vasc Surg* 2017;66:515-22. 10.1016/j.jvs.2017.02.033

28. McDermott MM, Liu K, Greenland P, Guralnik JM, Criqui MH, Chan C, et al. Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. *JAMA* 2004;292:453-61. 10.1001/jama.292.4.453

29. Gardner AW, Montgomery PS, Ritti-Dias RM, Forrester L. The effect of claudication pain on temporal and spatial gait measures during self-paced ambulation. *Vasc Med* 2010;15:21-6. 10.1177/1358863X09106836

30. Koutakis P, Johanning JM, Haynatzki GR, Myers SA, Stergiou N, Longo GM, et al. Abnormal joint powers before and after the onset of claudication symptoms. *J Vasc Surg* 2010;52:340-7. 10.1016/j.jvs.2010.03.005

31. Koutakis P, Pipinos, II, Myers SA, Stergiou N, Lynch TG, Johanning JM. Joint torques and powers are reduced during ambulation for both limbs in patients with unilateral claudication. *J Vasc Surg* 2010;51:80-8. 10.1016/j.jvs.2009.07.117

32. Schieber MN, Hasenkamp RM, Pipinos, II, Johanning JM, Stergiou N, DeSpiegelaere HK, et al. Muscle strength and control characteristics are altered by peripheral artery disease. *J Vasc Surg* 2017;66:178-86 e12. 10.1016/j.jvs.2017.01.051

33. Gardner AW, Montgomery PS. Impaired balance and higher prevalence of falls in subjects with intermittent claudication. *J Gerontol A Biol Sci Med Sci* 2001;56:M454-8.

34. Gohil RA, Mockford KA, Mazari F, Khan J, Vanicek N, Chetter IC, et al. Balance impairment, physical ability, and its link with disease severity in patients with intermittent claudication. *Ann Vasc Surg* 2013;27:68-74. 10.1016/j.avsg.2012.05.005

35. Chaudru S, Jehannin P, de Mullenheim PY, Klein H, Jaquinandi V, Mahe G, et al. Using wearable monitors to assess daily walking limitations induced by ischemic pain in peripheral artery disease. *Scand J Med Sci Sports* 2019;29:1813-26. 10.1111/sms.13511

36. McDermott MM, Guralnik JM, Tian L, Liu K, Ferrucci L, Liao Y, et al. Associations of borderline and low normal ankle-brachial index values with functional decline at 5-year follow-up: the WALCS (Walking and Leg Circulation Study). *J Am Coll Cardiol* 2009;53:1056-62. 10.1016/j.jacc.2008.09.063

37. Aboyans V, Criqui MH, Abraham P, Allison MA, Creager MA, Diehm C, et al. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. *Circulation* 2012;126:2890-909. 10.1161/CIR.0b013e318276fbcb

38. Treat-Jacobson D, McDermott MM, Beckman JA, Burt MA, Creager MA, Ehrman JK, et al. Implementation of Supervised Exercise Therapy for Patients With Symptomatic Peripheral Artery Disease: A Science Advisory From the American Heart Association. *Circulation* 2019;140:e700-e10. 10.1161/CIR.0000000000000727

39. Gardner AW, Skinner JS, Cantwell BW, Smith LK. Progressive vs single-stage treadmill tests for evaluation of claudication. *Med Sci Sports Exerc* 1991;23:402-8.

40. Hiatt WR, Hirsch AT, Regensteiner JG, Brass EP. Clinical trials for claudication. Assessment of exercise performance, functional status, and clinical end points. Vascular Clinical Trialists. *Circulation* 1995;92:614-21. 10.1161/01.cir.92.3.614

41. Hiatt WR, Rogers RK, Brass EP. The treadmill is a better functional test than the 6-minute walk test in therapeutic trials of patients with peripheral artery disease. *Circulation* 2014;130:69-78. 10.1161/CIRCULATIONAHA.113.007003

42. Nicolai SP, Viechtbauer W, Kruidenier LM, Candel MJ, Prins MH, Teijink JA. Reliability of treadmill testing in peripheral arterial disease: a meta-regression analysis. *J Vasc Surg* 2009;50:322-9. 10.1016/j.jvs.2009.01.042

43. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. *Am J Respir Crit Care Med* 2002;166:111-7. 10.1164/ajrccm.166.1.at1102

44. Chandra D, Kulkarni HS, Sciurba F. Learning from the learning effect in the six-minute-walk test. *Am J Respir Crit Care Med* 2012;185:684; author reply -5. 10.1164/ajrccm.185.6.684

45. Tew G, Copeland R, Le Faucheur A, Gernigon M, Nawaz S, Abraham P. Feasibility and validity of self-reported walking capacity in patients with intermittent claudication. *J Vasc Surg* 2013;57:1227-34. 10.1016/j.jvs.2012.02.073

46. McDermott MM, Guralnik JM, Criqui MH, Liu K, Kibbe MR, Ferrucci L. Six-minute walk is a better outcome measure than treadmill walking tests in therapeutic trials of patients with peripheral artery disease. *Circulation* 2014;130:61-8. 10.1161/CIRCULATIONAHA.114.007002

47. McDermott MM, Ades PA, Dyer A, Guralnik JM, Kibbe M, Criqui MH. Corridor-based functional performance measures correlate better with physical activity during daily life than treadmill measures in persons with peripheral arterial disease. *J Vasc Surg* 2008;48:1231-7, 7 e1. 10.1016/j.jvs.2008.06.050

48. McDermott MM, Guralnik JM, Tian L, Ferrucci L, Liu K, Liao Y, et al. Baseline functional performance predicts the rate of mobility loss in persons with peripheral arterial disease. *J Am Coll Cardiol* 2007;50:974-82. 10.1016/j.jacc.2007.05.030

49. Sandberg A, Cider A, Jivegard L, Nordanstig J, Wittboldt S, Back M. Test-retest reliability, agreement, and minimal detectable change in the 6-minute walk test in patients with intermittent claudication. *J Vasc Surg* 2020;71:197-203. 10.1016/j.jvs.2019.02.056

50. McDermott MM, Tian L, Criqui MH, Ferrucci L, Conte MS, Zhao L, et al. Meaningful change in 6-minute walk in people with peripheral artery disease. *J Vasc Surg* 2021;73:267-76 e1. 10.1016/j.jvs.2020.03.052

51. Gardner AW, Montgomery PS, Wang M. Minimal clinically important differences in treadmill, 6-minute walk, and patient-based outcomes following supervised and home-based exercise in peripheral artery disease. *Vasc Med* 2018;23:349-57. 10.1177/1358863X18762599

52. de Mullenheim PY, Chaudru S, Mahe G, Prioux J, Le Faucheur A. Clinical Interest of Ambulatory Assessment of Physical Activity and Walking Capacity in Peripheral Artery Disease. *Scand J Med Sci Sports* 2016;26:716-30. 10.1111/sms.12512

53. Abraham P, Noury-Desvaux B, Gernigon M, Mahe G, Sauvaget T, Leftheriotis G, et al. The inter- and intra-unit variability of a low-cost GPS data logger/receiver to study human outdoor walking in view of health and clinical studies. *PLoS One* 2012;7:e31338. 10.1371/journal.pone.0031338

54. Taoum A, Chaudru S, PY DEM, Congnard F, Emily M, Noury-Desvaux B, et al. Comparison of Activity Monitors Accuracy in Assessing Intermittent Outdoor Walking. *Med Sci Sports Exerc* 2021;53:1303-14. 10.1249/MSS.0000000000002587

55. Hochsmann C, Knaier R, Eymann J, Hintermann J, Infanger D, Schmidt-Trucksass A. Validity of activity trackers, smartphones, and phone applications to measure steps in various walking conditions. *Scand J Med Sci Sports* 2018;28:1818-27. 10.1111/sms.13074

56. Le Faucheur A, Abraham P, Jaquinandi V, Bouye P, Saumet JL, Noury-Desvaux B. Measurement of walking distance and speed in patients with peripheral arterial disease: a novel method using a global positioning system. *Circulation* 2008;117:897-904. 10.1161/CIRCULATIONAHA.107.725994

57. McDermott MM, Tian L, Ferrucci L, Liu K, Guralnik JM, Liao Y, et al. Associations between lower extremity ischemia, upper and lower extremity strength, and functional impairment with peripheral arterial disease. *J Am Geriatr Soc* 2008;56:724-9. 10.1111/j.1532-5415.2008.01633.x

58. Pizzimenti M, Meyer A, Charles AL, Giannini M, Chakfe N, Lejay A, et al. Sarcopenia and peripheral arterial disease: a systematic review. *J Cachexia Sarcopenia Muscle* 2020;11:866-86. 10.1002/jcsm.12587

59. Ritti-Dias RM, Basyches M, Camara L, Puech-Leao P, Battistella L, Wolosker N. Test-retest reliability of isokinetic strength and endurance tests in patients with intermittent claudication. *Vasc Med* 2010;15:275-8. 10.1177/1358863X10371415

60. Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. *J Gerontol* 1994;49:M85-94.

61. Lanzi S, Pousaz A, Calanca L, Mazzolai L. Sit to Stand Muscle Power Is Related to Functional Performance at Baseline and After Supervised Exercise Training in Patients with Lower Extremity Peripheral Artery Disease. *Eur J Vasc Endovasc Surg* 2023;65:521-7. 10.1016/j.ejvs.2022.12.029

62. Arndt H, Nordanstig J, Bertges DJ, Budtz-Lilly J, Venermo M, Espada CL, et al. A Delphi Consensus on Patient Reported Outcomes for Registries and Trials Including Patients with Intermittent Claudication: Recommendations and Reporting Standard. *Eur J Vasc Endovasc Surg* 2022;64:526-33. 10.1016/j.ejvs.2022.08.011

63. Raja A, Spertus J, Yeh RW, Secemsky EA. Assessing health-related quality of life among patients with peripheral artery disease: A review of the literature and focus on patient-reported outcome measures. *Vasc Med* 2021;26:317-25. 10.1177/1358863X20977016

64. Treat-Jacobson D, McDermott MM, Bronas UG, Campia U, Collins TC, Criqui MH, et al. Optimal Exercise Programs for Patients With Peripheral Artery Disease: A Scientific Statement From the American Heart Association. *Circulation* 2019;139:e10-e33. 10.1161/CIR.0000000000000623

65. Regensteiner JG, Hiatt WR, Coll JR, Criqui MH, Treat-Jacobson D, McDermott MM, et al. The impact of peripheral arterial disease on health-related quality of life in the Peripheral Arterial Disease Awareness, Risk, and Treatment: New Resources for Survival (PARTNERS) Program. *Vasc Med* 2008;13:15-24. 10.1177/1358863X07084911

66. Kim M, Kim Y, Ryu GW, Choi M. Functional Status and Health-Related Quality of Life in Patients with Peripheral Artery Disease: A Cross-Sectional Study. *Int J Environ Res Public Health* 2021;18:10.3390/ijerph182010941

67. Franco OH, de Laet C, Peeters A, Jonker J, Mackenbach J, Nusselder W. Effects of physical activity on life expectancy with cardiovascular disease. *Arch Intern Med* 2005;165:2355-60. 10.1001/archinte.165.20.2355

68. Dostalova R, Stillman C, Erickson KI, Slepicka P, Mudrak J. The Relationship between Physical Activity, Self-Perceived Health, and Cognitive Function in Older Adults. *Brain Sci* 2021;11:10.3390/brainsci11040492

69. Frank U, Nikol S, Belch J. 5 Conservative treatment for PAD - Risk factor management. *Vasa* 2019;48:1-12. 10.1024/0301-1526/a000835

70. Harwood A, Pymer S, Ingle L, Doherty P, Chetter I, Parmenter B, et al. Exercise training for intermittent claudication: a narrative review and summary of guidelines for practitioners. *BMJ Open Sport & Exercise Medicine* 2020;6:e000897. doi:10.1136/bmjsem-2020-000897

71. Gommans LN, Fokkenrood HJ, van Dalen HC, Scheltinga MR, Teijink JA, Peters RJ. Safety of supervised exercise therapy in patients with intermittent claudication. *J Vasc Surg* 2015;61:512-8 e2. 10.1016/j.jvs.2014.08.070

72. Bronas UG, Regensteiner JG. Connecting the past to the present: A historical review of exercise training for peripheral artery disease. *Vasc Med* 2022;27:174-85. 10.1177/1358863X211073620

73. Penin-Grandes S, Lopez-Ortiz S, Maroto-Izquierdo S, Menendez H, Pinto-Fraga J, Martin-Hernandez J, et al. Winners do what they fear: exercise and peripheral arterial disease-an umbrella review. *Eur J Prev Cardiol* 2023;10.1093/eurjpc/zwad261

74. Lane R, Harwood A, Watson L, Leng GC. Exercise for intermittent claudication. *Cochrane Database Syst Rev* 2017;12:CD000990. 10.1002/14651858.CD000990.pub4

75. Fakhry F, van de Luijtgaarden KM, Bax L, den Hoed PT, Hunink MG, Rouwet EV, et al. Supervised walking therapy in patients with intermittent claudication. *J Vasc Surg* 2012;56:1132-42. 10.1016/j.jvs.2012.04.046

76. Lanzi S, Boichat J, Calanca L, Aubertin P, Malatesta D, Mazzolai L. Gait changes after supervised exercise training in patients with symptomatic lower extremity peripheral artery disease. *Vasc Med* 2021;26:259-66. 10.1177/1358863X20984831

77. Lanzi S, Boichat J, Calanca L, Mazzolai L, Malatesta D. Supervised Exercise Training Improves 6 min Walking Distance and Modifies Gait Pattern during Pain-Free Walking Condition in Patients with Symptomatic Lower Extremity Peripheral Artery Disease. *Sensors (Basel)* 2021;21:7989. 10.3390/s21237989

78. Fassora M, Calanca L, Jaques C, Mazzolai L, Kayser B, Lanzi S. Intensity-dependent effects of exercise therapy on walking performance and aerobic fitness in symptomatic patients with lower-extremity peripheral artery disease: A systematic review and meta-analysis. *Vasc Med* 2022;27:158-70. 10.1177/1358863X211034577

79. Lanzi S, Pousaz A, Calanca L, Mazzolai L. Time-course evolution of functional performance during a 3-month supervised exercise training program in patients with symptomatic peripheral artery disease. *Vasc Med* 2023;1358863X231191908. 10.1177/1358863X231191908

80. Parmenter BJ, Dieberg G, Phipps G, Smart NA. Exercise training for health-related quality of life in peripheral artery disease: a systematic review and meta-analysis. *Vasc Med* 2015;20:30-40. 10.1177/1358863X14559092

81. Parmenter BJ, Dieberg G, Smart NA. Exercise training for management of peripheral arterial disease: a systematic review and meta-analysis. *Sports Med* 2015;45:231-44. 10.1007/s40279-014-0261-z

82. Schieber MN, Pipinos, II, Johanning JM, Casale GP, Williams MA, DeSpiegelaere HK, et al. Supervised walking exercise therapy improves gait biomechanics in patients with peripheral artery disease. *J Vasc Surg* 2019;71:575-83. 10.1016/j.jvs.2019.05.044

83. Siercke M, Jorgensen LP, Missel M, Thygesen LC, Moller SP, Sillesen H, et al. Cardiovascular Rehabilitation Increases Walking Distance in Patients With Intermittent Claudication. Results of the CIPIC Rehab Study: A Randomised Controlled Trial. *Eur J Vasc Endovasc Surg* 2021;62:768-76. 10.1016/j.ejvs.2021.04.004

84. Brown T, Forster RB, Cleanthis M, Mikhailidis DP, Stansby G, Stewart M. Cilostazol for intermittent claudication. *Cochrane Database Syst Rev* 2021;6:CD003748. 10.1002/14651858.CD003748.pub5

85. De Haro J, Bleda S, Varela C, Esparza L, Acin F, Bosentan Population-Based Randomized Trial for C, et al. Effect of Bosentan on Claudication Distance and Endothelium-Dependent Vasodilation in Hispanic Patients With Peripheral Arterial Disease. *Am J Cardiol* 2016;117:295-301. 10.1016/j.amjcard.2015.10.032

86. Omarjee L, Le Pabic E, Custaud MA, Fontaine C, Locher C, Renault A, et al. Effects of sildenafil on maximum walking time in patients with arterial claudication: The ARTERIOFIL study. *Vascul Pharmacol* 2019;118-119:106563. 10.1016/j.vph.2019.05.003

87. Suzuki J, Shimamura M, Suda H, Wakayama K, Kumagai H, Ikeda Y, et al. Current therapies and investigational drugs for peripheral arterial disease. *Hypertens Res* 2016;39:183-91. 10.1038/hr.2015.134

88. Broderick C, Forster R, Abdel-Hadi M, Salhiyyah K. Pentoxifylline for intermittent claudication. *Cochrane Database Syst Rev* 2020;10:CD005262. 10.1002/14651858.CD005262.pub4

89. Jansen SC, Abaraogu UO, Lauret GJ, Fakhry F, Fokkenrood HJ, Teijink JA. Modes of exercise training for intermittent claudication. *Cochrane Database Syst Rev* 2020;8:CD009638. 10.1002/14651858.CD009638.pub3

90. Parmenter BJ, Raymond J, Dinnen P, Lusby RJ, Fiatarone Singh MA. High-intensity progressive resistance training improves flat-ground walking in older adults with symptomatic peripheral arterial disease. *J Am Geriatr Soc* 2013;61:1964-70. 10.1111/jgs.12500

91. Ritti-Dias RM, Wolosker N, de Moraes Forjaz CL, Carvalho CR, Cucato GG, Leao PP, et al. Strength training increases walking tolerance in intermittent claudication patients: randomized trial. *J Vasc Surg* 2010;51:89-95. 10.1016/j.jvs.2009.07.118

92. Sanderson B, Askew C, Stewart I, Walker P, Gibbs H, Green S. Short-term effects of cycle and treadmill training on exercise tolerance in peripheral arterial disease. *J Vasc Surg* 2006;44:119-27. 10.1016/j.jvs.2006.03.037

93. Collins EG, Edwin Langbein W, Orebaugh C, Bammert C, Hanson K, Reda D, et al. PoleStriding exercise and vitamin E for management of peripheral vascular disease. *Med Sci Sports Exerc* 2003;35:384-93. 10.1249/01.MSS.0000053658.82687.FF

94. Collins EG, Langbein WE, Orebaugh C, Bammert C, Hanson K, Reda D, et al. Cardiovascular training effect associated with polestriding exercise in patients with peripheral arterial disease. *J Cardiovasc Nurs* 2005;20:177-85.

95. Calanca L, Lanzi S, Ney B, Berchtold A, Mazzolai L. Multimodal Supervised Exercise Significantly Improves Walking Performances Without Changing Hemodynamic Parameters in Patients With Symptomatic Lower Extremity Peripheral Artery Disease. *Vasc Endovascular Surg* 2020;54:605-11. 10.1177/1538574420940090

96. Lanzi S, Calanca L, Berchtold A, Mazzolai L. Improvement in 6-Minute Walking Distance after Supervised Exercise Training Is Related to Changes in Quality of Life in Patients with Lower Extremity Peripheral Artery Disease. *J Clin Med* 2021;10:3330. 10.3390/jcm10153330

97. Lanzi S, Calanca L, Borgeat Kaeser A, Mazzolai L. Walking performances and muscle oxygen desaturation are increased after supervised exercise training in Takayasu arteritis: a case report and a review of the literature. *Eur Heart J Case Rep* 2018;2:yty123. 10.1093/ehjcr/yty123

98. Ney B, Lanzi S, Calanca L, Mazzolai L. Multimodal Supervised Exercise Training Is Effective in Improving Long Term Walking Performance in Patients with Symptomatic Lower Extremity Peripheral Artery Disease. *J Clin Med* 2021;10:2057. 10.3390/jcm10102057

99. Tew G, Nawaz S, Zwierska I, Saxton JM. Limb-specific and cross-transfer effects of arm-crank exercise training in patients with symptomatic peripheral arterial disease. *Clin Sci (Lond)* 2009;117:405-13. 10.1042/CS20080688

100. Treat-Jacobson D, Bronas UG, Leon AS. Efficacy of arm-ergometry versus treadmill exercise training to improve walking distance in patients with claudication. *Vasc Med* 2009;14:203-13. 10.1177/1358863X08101858

101. Parmenter BJ, Raymond J, Dinnen P, Singh MA. A systematic review of randomized controlled trials: Walking versus alternative exercise prescription as treatment for intermittent claudication. *Atherosclerosis* 2011;218:1-12. 10.1016/j.atherosclerosis.2011.04.024

102. McDermott MM, Ades P, Guralnik JM, Dyer A, Ferrucci L, Liu K, et al. Treadmill exercise and resistance training in patients with peripheral arterial disease with and without intermittent claudication: a randomized controlled trial. *JAMA* 2009;301:165-74. 10.1001/jama.2008.962

103. Bulmer AC, Coombes JS. Optimising exercise training in peripheral arterial disease. *Sports Med* 2004;34:983-1003. 10.2165/00007256-200434140-00004

104. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. *JAMA* 1995;274:975-80.

105. Borg GA. Psychophysical bases of perceived exertion. *Med Sci Sports Exerc* 1982;14:377-81.

106. Au TB, Golledge J, Walker PJ, Haigh K, Nelson M. Peripheral arterial disease - diagnosis and management in general practice. *Aust Fam Physician* 2013;42:397-400.

107. Hammond MM, Spring B, Rejeski WJ, Sufit R, Criqui MH, Tian L, et al. Effects of Walking Exercise at a Pace With Versus Without Ischemic Leg Symptoms on Functional Performance Measures in People With Lower Extremity Peripheral Artery Disease: The LITE Randomized Clinical Trial. *J Am Heart Assoc* 2022;11:e025063. 10.1161/JAHA.121.025063

108. McDermott MM, Spring B, Tian L, Treat-Jacobson D, Ferrucci L, Lloyd-Jones D, et al. Effect of Low-Intensity vs High-Intensity Home-Based Walking Exercise on Walk Distance in Patients With Peripheral Artery Disease: The LITE Randomized Clinical Trial. *JAMA* 2021;325:1266-76. 10.1001/jama.2021.2536

109. Mika P, Konik A, Januszek R, Petriczek T, Mika A, Nowobilski R, et al. Comparison of two treadmill training programs on walking ability and endothelial function in intermittent claudication. *Int J Cardiol* 2013;168:838-42. 10.1016/j.ijcard.2012.10.003

110. Novakovic M, Krevel B, Rajkovic U, Vizintin Cuderman T, Jansa Trontelj K, Fras Z, et al. Moderate-pain versus pain-free exercise, walking capacity, and cardiovascular health in patients with peripheral artery disease. *J Vasc Surg* 2019;70:148-56. 10.1016/j.jvs.2018.10.109

111. Perks J, Zaccardi F, Paterson C, Houghton JSM, Nickinson ATO, Pepper CJ, et al. Effect of high-pain versus low-pain structured exercise on walking ability in people with intermittent claudication: meta-analysis. *Br J Surg* 2022;109:686-94. 10.1093/bjs/znac134

112. Seed SA, Harwood AE, Sinclair J, Pymer S, Caldow E, Ingle L, et al. A Systematic Review of Exercise Prescription in Patients with Intermittent Claudication: Does Pain Matter? *Ann Vasc Surg* 2021;77:315-23. 10.1016/j.avsg.2021.06.025

113. Birkett ST, Sinclair J, Seed SA, Pymer S, Caldow E, Ingle L, et al. Effects of exercise prescribed at different levels of claudication pain on walking performance in patients with intermittent claudication: a protocol for a randomised controlled trial. *Ther Adv Cardiovasc Dis* 2022;16:17539447221108817. 10.1177/17539447221108817

114. Lanzi S, Mazzolai L. Commentary to Seed et al. 'What is the correct level of claudication pain to prescribe? Universal inconsistency within guidelines, a painful issue'. *Vascular* 2023;17085381231160931. 10.1177/17085381231160931

115. Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, et al. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. *Med Sci Sports Exerc* 2011;43:1334-59. 10.1249/MSS.0b013e318213fefb

116. Hansen D, Abreu A, Ambrosetti M, Cornelissen V, Gevaert A, Kemps H, et al. Exercise intensity assessment and prescription in cardiovascular rehabilitation and beyond: why and how: a position statement from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. *Eur J Prev Cardiol* 2022;29:230-45. 10.1093/eurjpc/zwab007

117. Wood TM, Maddalozzo GF, Harter RA. Accuracy of Seven Equations for Predicting 1-RM Performance of Apparently Healthy, Sedentary Older Adults. *Measurement in Physical Education and Exercise Science* 2002;6:67-94. 10.1207/S15327841MPEE0602\_1

118. Parmenter BJ, Mavros Y, Ritti Dias R, King S, Fiatarone Singh M. Resistance training as a treatment for older persons with peripheral artery disease: a systematic review and meta-analysis. *Br J Sports Med* 2019;54:452-61. 10.1136/bjsports-2018-100205

119. Pymer S, Ibeggazene S, Palmer J, Tew GA, Ingle L, Smith GE, et al. An updated systematic review and meta-analysis of home-based exercise programs for individuals with intermittent claudication. *J Vasc Surg* 2021;74:2076-85 e20. 10.1016/j.jvs.2021.03.063

120. van den Houten MML, Hageman D, Gommans LNM, Kleijnen J, Scheltinga MRM, Teijink JAW. The Effect of Supervised Exercise, Home Based Exercise and Endovascular Revascularisation on Physical Activity in Patients With Intermittent Claudication: A Network Meta-analysis. *Eur J Vasc Endovasc Surg* 2019;58:383-92. 10.1016/j.ejvs.2018.12.023

121. Rejeski WJ, Spring B, Domanchuk K, Tao H, Tian L, Zhao L, et al. A group-mediated, home-based physical activity intervention for patients with peripheral artery disease: effects on social and psychological function. *J Transl Med* 2014;12:29. 10.1186/1479-5876-12-29

122. Fakhry F, Spronk S, de Ridder M, den Hoed PT, Hunink MG. Long-term effects of structured home-based exercise program on functional capacity and quality of life in patients with intermittent claudication. *Arch Phys Med Rehabil* 2011;92:1066-73. 10.1016/j.apmr.2011.02.007

123. McDermott MM, Guralnik JM, Criqui MH, Ferrucci L, Zhao L, Liu K, et al. Home-based walking exercise in peripheral artery disease: 12-month follow-up of the GOALS randomized trial. *J Am Heart Assoc* 2014;3:e000711. 10.1161/JAHA.113.000711

124. Waddell A, Seed S, Broom DR, McGregor G, Birkett ST, Harwood AE. Safety of home-based exercise for people with intermittent claudication: A systematic review. *Vasc Med* 2022;27:186-92. 10.1177/1358863X211060388

125. Lamberti N, Lopez-Soto PJ, Guerzoni F, Napoli N, Gasbarro V, Zamboni P, et al. Changes in exercise capacity and risk of all-cause mortality in patients with peripheral artery disease: a 10-year retrospective cohort study. *Intern Emerg Med* 2020;15:289-98. 10.1007/s11739-019-02176-3

126. Hageman D, Fokkenrood HJ, Gommans LN, van den Houten MM, Teijink JA. Supervised exercise therapy versus home-based exercise therapy versus walking advice for intermittent claudication. *Cochrane Database Syst Rev* 2018;4:CD005263. 10.1002/14651858.CD005263.pub4

127. Al-Jundi W, Madbak K, Beard JD, Nawaz S, Tew GA. Systematic review of home-based exercise programmes for individuals with intermittent claudication. *Eur J Vasc Endovasc Surg* 2013;46:690-706. 10.1016/j.ejvs.2013.09.004

128. Dua A, Gologorsky R, Savage D, Rens N, Gandhi N, Brooke B, et al. National assessment of availability, awareness, and utilization of supervised exercise therapy for peripheral artery disease patients with intermittent claudication. *J Vasc Surg* 2020;71:1702-7. 10.1016/j.jvs.2019.08.238

129. Haque A. Few UK vascular centres offer a fully NICE-compliant supervised exercise programme: a national audit. *Ann R Coll Surg Engl* 2021;10.1308/rcsann.2021.0126

130. Harwood AE, Pymer S, Ibeggazene S, Ingle L, Caldow E, Birkett ST. Provision of exercise services in patients with peripheral artery disease in the United Kingdom. *Vascular* 2021;17085381211035259. 10.1177/17085381211035259

131. Makris GC, Lattimer CR, Lavida A, Geroulakos G. Availability of supervised exercise programs and the role of structured home-based exercise in peripheral arterial disease. *Eur J Vasc Endovasc Surg* 2012;44:569-75; discussion 76. 10.1016/j.ejvs.2012.09.009

132. Gardner AW, Parker DE, Montgomery PS, Blevins SM. Diabetic women are poor responders to exercise rehabilitation in the treatment of claudication. *J Vasc Surg* 2014;59:1036-43. 10.1016/j.jvs.2013.10.058

133. Manfredini R, Lamberti N, Manfredini F, Straudi S, Fabbian F, Rodriguez Borrego MA, et al. Gender Differences in Outcomes Following a Pain-Free, Home-Based Exercise Program for Claudication. *J Womens Health (Larchmt)* 2019;28:1313-21. 10.1089/jwh.2018.7113

134. Gardner AW, Parker DE, Montgomery PS. Sex-specific predictors of improved walking with step-monitored, home-based exercise in peripheral artery disease. *Vasc Med* 2015;20:424-31. 10.1177/1358863X15596237

135. Collins TC, Lunos S, Carlson T, Henderson K, Lightbourne M, Nelson B, et al. Effects of a home-based walking intervention on mobility and quality of life in people with diabetes and peripheral arterial disease: a randomized controlled trial. *Diabetes Care* 2011;34:2174-9. 10.2337/dc10-2399

136. Lamberti N, Malagoni AM, Ficarra V, Basaglia N, Manfredini R, Zamboni P, et al. Structured Home-Based Exercise Versus Invasive Treatment: A Mission Impossible? A Pilot Randomized Study in Elderly Patients With Intermittent Claudication. *Angiology* 2016;67:772-80. 10.1177/0003319715618481

137. McDermott MM, Polonsky TS. Home-Based Exercise: A Therapeutic Option for Peripheral Artery Disease. *Circulation* 2016;134:1127-9. 10.1161/CIRCULATIONAHA.116.023691

138. Chan C, Sounderajah V, Normahani P, Acharya A, Markar SR, Darzi A, et al. Wearable Activity Monitors in Home Based Exercise Therapy for Patients with Intermittent Claudication: A Systematic Review. *Eur J Vasc Endovasc Surg* 2021;61:676-87. 10.1016/j.ejvs.2020.11.044

139. Kim M, Kim C, Kim E, Choi M. Effectiveness of Mobile Health-Based Exercise Interventions for Patients with Peripheral Artery Disease: Systematic Review and Meta-Analysis. *JMIR Mhealth Uhealth* 2021;9:e24080. 10.2196/24080

140. Hawley JA, Hargreaves M, Joyner MJ, Zierath JR. Integrative biology of exercise. *Cell* 2014;159:738-49. 10.1016/j.cell.2014.10.029

141. Hoier B, Hellsten Y. Exercise-induced capillary growth in human skeletal muscle and the dynamics of VEGF. *Microcirculation* 2014;21:301-14. 10.1111/micc.12117

142. Egginton S. Invited review: activity-induced angiogenesis. *Pflugers Arch* 2009;457:963-77. 10.1007/s00424-008-0563-9

143. Handschin C, Spiegelman BM. The role of exercise and PGC1alpha in inflammation and chronic disease. *Nature* 2008;454:463-9. 10.1038/nature07206

144. Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol* 2017;69:1465-508. 10.1016/j.jacc.2016.11.008

145. Heiss C, Olinic DM, Belch JJF, Brodmann M, Mazzolai L, Stanek A, et al. Management of chronic peripheral artery disease patients with indication for endovascular revascularization. *Vasa* 2022;10.1024/0301-1526/a000998

146. Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, et al. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 2013;127:1425-43. 10.1161/CIR.0b013e31828b82aa

147. Koelemay MJW, van Reijen NS, van Dieren S, Frans FA, Vermeulen EJG, Buscher H, et al. Editor's Choice - Randomised Clinical Trial of Supervised Exercise Therapy vs. Endovascular Revascularisation for Intermittent Claudication Caused by Iliac Artery Obstruction: The SUPER study. *Eur J Vasc Endovasc Surg* 2022;63:421-9. 10.1016/j.ejvs.2021.09.042

148. Murphy TP, Cutlip DE, Regensteiner JG, Mohler ER, Cohen DJ, Reynolds MR, et al. Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study. *Circulation* 2012;125:130-9. 10.1161/CIRCULATIONAHA.111.075770

149. Murphy TP, Cutlip DE, Regensteiner JG, Mohler ER, 3rd, Cohen DJ, Reynolds MR, et al. Supervised exercise, stent revascularization, or medical therapy for claudication due to aortoiliac peripheral artery disease: the CLEVER study. *J Am Coll Cardiol* 2015;65:999-1009. 10.1016/j.jacc.2014.12.043

150. Koppe-Schmeisser F, Schwaderlapp M, Schmeisser J, Dopheide JF, Munzel T, Daiber A, et al. Influence of Peripheral Transluminal Angioplasty Alongside Exercise Training on Oxidative Stress and Inflammation in Patients with Peripheral Arterial Disease. *J Clin Med* 2021;10:10.3390/jcm10245851

151. Pandey A, Banerjee S, Ngo C, Mody P, Marso SP, Brilakis ES, et al. Comparative Efficacy of Endovascular Revascularization Versus Supervised Exercise Training in Patients With Intermittent Claudication: Meta-Analysis of Randomized Controlled Trials. *JACC Cardiovasc Interv* 2017;10:712-24. 10.1016/j.jcin.2017.01.027

152. Fakhry F, Fokkenrood HJ, Spronk S, Teijink JA, Rouwet EV, Hunink MGM. Endovascular revascularisation versus conservative management for intermittent claudication. *Cochrane Database Syst Rev* 2018;3:CD010512. 10.1002/14651858.CD010512.pub2

153. Badger SA, Soong CV, O'Donnell ME, Boreham CA, McGuigan KE. Benefits of a supervised exercise program after lower limb bypass surgery. *Vasc Endovascular Surg* 2007;41:27-32. 10.1177/1538574406296209

154. Kobayashi T, Hamamoto M, Okazaki T, Honma T, Iba K, Takakuwa T, et al. Effectiveness of continuous unsupervised exercise therapy after above-knee femoropopliteal bypass. *Vascular* 2021;29:387-95. 10.1177/1708538120957488

155. Meneses AL, Ritti-Dias RM, Parmenter B, Golledge J, Askew CD. Combined Lower Limb Revascularisation and Supervised Exercise Training for Patients with Peripheral Arterial Disease: A Systematic Review of Randomised Controlled Trials. *Sports Med* 2017;47:987-1002. 10.1007/s40279-016-0635-5

156. Issa SM, Hoeks SE, Scholte op Reimer WJ, Van Gestel YR, Lenzen MJ, Verhagen HJ, et al. Health-related quality of life predicts long-term survival in patients with peripheral artery disease. *Vasc Med* 2010;15:163-9. 10.1177/1358863X10364208

157. Gardner AW, Parker DE, Montgomery PS, Scott KJ, Blevins SM. Efficacy of quantified home-based exercise and supervised exercise in patients with intermittent claudication: a randomized controlled trial. *Circulation* 2011;123:491-8. 10.1161/CIRCULATIONAHA.110.963066

158. Patterson RB, Pinto B, Marcus B, Colucci A, Braun T, Roberts M. Value of a supervised exercise program for the therapy of arterial claudication. *J Vasc Surg* 1997;25:312-8. 10.1016/s0741-5214(97)70352-5

159. Tsai JC, Chan P, Wang CH, Jeng C, Hsieh MH, Kao PF, et al. The effects of exercise training on walking function and perception of health status in elderly patients with peripheral arterial occlusive disease. *J Intern Med* 2002;252:448-55. 10.1046/j.1365-2796.2002.01055.x

160. Nicolai SP, Teijink JA, Prins MH, Exercise Therapy in Peripheral Arterial Disease Study G. Multicenter randomized clinical trial of supervised exercise therapy with or without feedback versus walking advice for intermittent claudication. *J Vasc Surg* 2010;52:348-55. 10.1016/j.jvs.2010.02.022

161. Guidon M, McGee H. Exercise-based interventions and health-related quality of life in intermittent claudication: a 20-year (1989-2008) review. *Eur J Cardiovasc Prev Rehabil* 2010;17:140-54. 10.1097/HJR.0b013e3283377f08

162. Guidon M, McGee H. One-year effect of a supervised exercise programme on functional capacity and quality of life in peripheral arterial disease. *Disabil Rehabil* 2013;35:397-404. 10.3109/09638288.2012.694963

163. Kakkos SK, Geroulakos G, Nicolaides AN. Improvement of the walking ability in intermittent claudication due to superficial femoral artery occlusion with supervised exercise and pneumatic foot and calf compression: a randomised controlled trial. *Eur J Vasc Endovasc Surg* 2005;30:164-75. 10.1016/j.ejvs.2005.03.011

164. Savage P, Ricci MA, Lynn M, Gardner A, Knight S, Brochu M, et al. Effects of home versus supervised exercise for patients with intermittent claudication. *J Cardiopulm Rehabil* 2001;21:152-7. 10.1097/00008483-200105000-00006

165. Gardner AW, Montgomery PS, Wang M, Xu C. Predictors of health-related quality of life in patients with symptomatic peripheral artery disease. *J Vasc Surg* 2018;68:1126-34. 10.1016/j.jvs.2017.12.074

166. Erickson KI, Hillman C, Stillman CM, Ballard RM, Bloodgood B, Conroy DE, et al. Physical Activity, Cognition, and Brain Outcomes: A Review of the 2018 Physical Activity Guidelines. *Med Sci Sports Exerc* 2019;51:1242-51. 10.1249/MSS.0000000000001936

167. Kirk-Sanchez NJ, McGough EL. Physical exercise and cognitive performance in the elderly: current perspectives. *Clin Interv Aging* 2014;9:51-62. 10.2147/CIA.S39506

168. Gomez-Pinilla F, Hillman C. The influence of exercise on cognitive abilities. *Compr Physiol* 2013;3:403-28. 10.1002/cphy.c110063

169. Gommans LN, Saarloos R, Scheltinga MR, Houterman S, de Bie RA, Fokkenrood HJ, et al. Editor's choice--The effect of supervision on walking distance in patients with intermittent claudication: a meta-analysis. *Eur J Vasc Endovasc Surg* 2014;48:169-84. 10.1016/j.ejvs.2014.04.019

170. Abaraogu UO, Dall PM, Seenan CA. The Effect of Structured Patient Education on Physical Activity in Patients with Peripheral Arterial Disease and Intermittent Claudication: A Systematic Review. *Eur J Vasc Endovasc Surg* 2017;54:58-68. 10.1016/j.ejvs.2017.04.003

171. Bearne LM, Volkmer B, Peacock J, Sekhon M, Fisher G, Galea Holmes MN, et al. Effect of a Home-Based, Walking Exercise Behavior Change Intervention vs Usual Care on Walking in Adults With Peripheral Artery Disease: The MOSAIC Randomized Clinical Trial. *JAMA* 2022;327:1344-55. 10.1001/jama.2022.3391

172. McDermott MM, Liu K, Guralnik JM, Criqui MH, Spring B, Tian L, et al. Home-based walking exercise intervention in peripheral artery disease: a randomized clinical trial. *JAMA* 2013;310:57-65. 10.1001/jama.2013.7231

173. McDermott MM, Spring B, Berger JS, Treat-Jacobson D, Conte MS, Creager MA, et al. Effect of a Home-Based Exercise Intervention of Wearable Technology and Telephone Coaching on Walking Performance in Peripheral Artery Disease: The HONOR Randomized Clinical Trial. *JAMA* 2018;319:1665-76. 10.1001/jama.2018.3275

174. Behrendt CA, Thomalla G, Rimmele DL, Petersen EL, Twerenbold R, Debus ES, et al. Prevalence of peripheral arterial disease, abdominal aortic aneurysm, and risk factors in the Hamburg City Health Study: A Cross-Sectional Analysis. *Eur J Vasc Endovasc Surg* 2023;10.1016/j.ejvs.2023.01.002

175. Pabon M, Cheng S, Altin SE, Sethi SS, Nelson MD, Moreau KL, et al. Sex Differences in Peripheral Artery Disease. *Circ Res* 2022;130:496-511. 10.1161/CIRCRESAHA.121.320702

176. Behrendt CA, Sigvant B, Kuchenbecker J, Grima MJ, Schermerhorn M, Thomson IA, et al. Editor's Choice - International Variations and Sex Disparities in the Treatment of Peripheral Arterial Occlusive Disease: A Report from VASCUNET and the International Consortium of Vascular Registries. *Eur J Vasc Endovasc Surg* 2020;60:873-80. 10.1016/j.ejvs.2020.08.027

177. Detriche G, Guedon A, Mohamedi N, Sellami O, Cheng C, Galloula A, et al. Women Specific Characteristics and 1-Year Outcome Among Patients Hospitalized for Peripheral Artery Disease: A Monocentric Cohort Analysis in a Tertiary Center. *Front Cardiovasc Med* 2022;9:824466. 10.3389/fcvm.2022.824466

178. Heidemann F, Kuchenbecker J, Peters F, Kotov A, Marschall U, L'Hoest H, et al. A health insurance claims analysis on the effect of female sex on long-term outcomes after peripheral endovascular interventions for symptomatic peripheral arterial occlusive disease. *J Vasc Surg* 2021;74:780-7 e7. 10.1016/j.jvs.2021.01.066

179. Hirsch AT, Allison MA, Gomes AS, Corriere MA, Duval S, Ershow AG, et al. A call to action: women and peripheral artery disease: a scientific statement from the American Heart Association. *Circulation* 2012;125:1449-72. 10.1161/CIR.0b013e31824c39ba

180. Kotov A, Heidemann F, Kuchenbecker J, Peters F, Marschall U, Acar L, et al. Sex Disparities in Long Term Outcomes After Open Surgery for Chronic Limb Threatening Ischaemia: A Propensity Score Matched Analysis of Health Insurance Claims. *Eur J Vasc Endovasc Surg* 2021;61:423-9. 10.1016/j.ejvs.2020.11.006

181. Singh N, Liu K, Tian L, Criqui MH, Guralnik JM, Ferrucci L, et al. Leg strength predicts mortality in men but not in women with peripheral arterial disease. *J Vasc Surg* 2010;52:624-31. 10.1016/j.jvs.2010.03.066

182. McDermott MM, Ferrucci L, Liu K, Guralnik JM, Tian L, Kibbe M, et al. Women with peripheral arterial disease experience faster functional decline than men with peripheral arterial disease. *J Am Coll Cardiol* 2011;57:707-14. 10.1016/j.jacc.2010.09.042

183. Gommans LN, Scheltinga MR, van Sambeek MR, Maas AH, Bendermacher BL, Teijink JA. Gender differences following supervised exercise therapy in patients with intermittent claudication. *J Vasc Surg* 2015;62:681-8. 10.1016/j.jvs.2015.03.076

184. Regensteiner JG, Bauer TA, Reusch JE, Brandenburg SL, Sippel JM, Vogelsong AM, et al. Abnormal oxygen uptake kinetic responses in women with type II diabetes mellitus. *J Appl Physiol (1985)* 1998;85:310-7. 10.1152/jappl.1998.85.1.310

185. Lanzi S, Pousaz A, Calanca L, Mazzolai L. Sex-based differences in supervised exercise therapy outcomes for symptomatic peripheral artery disease. *Vasc Med* 2023;1358863X221149454. 10.1177/1358863X221149454

186. Cetlin MD, Polonsky T, Ho K, Zhang D, Tian L, Zhao L, et al. Barriers to participation in supervised exercise therapy reported by people with peripheral artery disease. *J Vasc Surg* 2023;77:506-14. 10.1016/j.jvs.2022.09.014

187. Gupta T, Manning P, Kolte D, Smolderen KG, Stone N, Henry JG, et al. Exercise therapy referral and participation in patients with peripheral artery disease: Insights from the PORTRAIT registry. *Vasc Med* 2021;26:654-6. 10.1177/1358863X211033649

188. Harwood A, Smith G, Broadbent E, Cayton T, Carradice D, Chetter I. Access to supervised exercise services for peripheral vascular disease patients. *Bull R Coll Surgeons Engl* 2017;99:207–11.

189. Harwood AE, Smith GE, Cayton T, Broadbent E, Chetter IC. A Systematic Review of the Uptake and Adherence Rates to Supervised Exercise Programs in Patients with Intermittent Claudication. *Ann Vasc Surg* 2016;34:280-9. 10.1016/j.avsg.2016.02.009

190. Li Y, Rother U, Rosenberg Y, Hinterseher I, Uhl C, Mylonas S, et al. A prospective survey study on the education and awareness about walking exercise amongst inpatients with symptomatic peripheral arterial disease in Germany. *Vasa* 2023;52:218-23. 10.1024/0301-1526/a001057

191. Rother U, Dorr G, Malyar N, Muller OJ, Steinbauer M, Ito W, et al. How German vascular surgeons and angiologists judge walking exercise for patients with PAD. *Vasa* 2023;52:224-9. 10.1024/0301-1526/a001071

192. Saxon JT, Safley DM, Mena-Hurtado C, Heyligers J, Fitridge R, Shishehbor M, et al. Adherence to Guideline-Recommended Therapy-Including Supervised Exercise Therapy Referral-Across Peripheral Artery Disease Specialty Clinics: Insights From the International PORTRAIT Registry. *J Am Heart Assoc* 2020;9:e012541. 10.1161/JAHA.119.012541

193. Lanzi S, Belch J, Brodmann M, Madaric J, Bura-Riviere A, Visona A, et al. Supervised exercise training in patients with lower extremity peripheral artery disease. *Vasa* 2022;51:267-74. 10.1024/0301-1526/a001024

194. Parodi JC, Fernandez S, Moscovich F, Pulmaria C. Hydration may reverse most symptoms of lower extremity intermittent claudication or rest pain. *J Vasc Surg* 2020;72:1459-63. 10.1016/j.jvs.2020.05.066

195. Mannarino E, Pasqualini L, Innocente S, Scricciolo V, Rignanese A, Ciuffetti G. Physical training and antiplatelet treatment in stage II peripheral arterial occlusive disease: alone or combined? *Angiology* 1991;42:513-21. 10.1177/000331979104200701

196. Hobbs SD, Marshall T, Fegan C, Adam DJ, Bradbury AW. The effect of supervised exercise and cilostazol on coagulation and fibrinolysis in intermittent claudication: a randomized controlled trial. *J Vasc Surg* 2007;45:65-70; discussion 10.1016/j.jvs.2006.08.084

**Figures titles and abbreviations**

**Structured Graphical Abstract.** Graphical summary of the exercise training approaches in patients with peripheral artery disease.

**Figure 1.** Pathophysiology of limb symptoms in peripheral artery disease.

**Figure 2.** Algorithm of chronic symptomatic patients with PAD with indication for exercise treatment. *PAD = peripheral artery disease; SPPB = short physical performance battery; BMT = best medical treatment (including pharmacological and non-pharmacological (lifestyle changes, exercise) approach); DUS = Duplex ultrasound; SF-36 = short-form health 36 questionnaire; WIQ =* Walking Impairment Questionnaire; *Vascu-QoL6 = Vascular Quality of Life Questionnaire-6.*

**Figure 3.** Dynamic exercise training induces extensive remodeling of the vascular system. *Skeletal muscle contraction is associated with several physiological, metabolic and mechanical mechanisms that when repeated over several weeks and months, result in mitochondrial biogenesis, angiogenesis, and increases in the functional capacity of individuals with peripheral arterial disease. AMPK = AMP-activated protein kinase; PGC-1 = peroxisome proliferator-activated receptor gamma coactivator-1; HIF-1 = hypoxia inducible factor 1-alpha; ERR = Estrogen-related receptor alpha; VEGF = Vascular endothelial growth factor; NO = nitric oxide; ROS = reactive oxygen species; PGI2 = prostacyclin; CRP = C-reactive protein; IL-6 = interleukin-6; slCAM-1 = soluble intercellular adhesion molecule-1; sVCAM-1 = circulating vascular cell adhesion molecule-1.*